Management of Asymptomatic Arrhythmias: A European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS)

David O. Arnar (Iceland, Chair), Georges H. Mairesse (Belgium, co-Chair), Giuseppe Boriani (Italy), Hugh Calkins (USA, HRS representative), Ashley Chin (South Africa, CASSA representative), Andrew Coats (United Kingdom, HFA representative), Jean-Claude Deharo (France), Jesper Hastrup Svendsen (Denmark), Hein Heidbüchel (Belgium), Rodrigo Isa (Chile, LAHRS representative), Jonathan M. Kalman (Australia, APHRS representative), Deirdre A. Lane (United Kingdom), Ruan Louw (South Africa, CASSA representative), Gregory Y. H. Lip (United Kingdom, Denmark), Philippe Maury (France), Tatjana Potpara (Serbia), Frederic Sacher (France), Prashanthan Sanders (Australia, APHRS representative), Niraj Varma (USA, HRS representative), and Laurent Fauchier (France).

1Department of Medicine, Landspitali - The National University Hospital of Iceland and University of Iceland, Reykjavik, Iceland, 2Department of Cardiology, Cliniques du Sud-Luxembourg, Arlon, Belgium, 3Cardiology Division, Department of Diagnostics, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy, 4Department of Arrhythmia Services, Johns Hopkins Medical Institutions Baltimore, Maryland, USA, 5Division of Cardiology, Department of Medicine, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa, 6Department of Cardiology, University of Warwick, Warwickshire, United Kingdom, 7Department of Rhythmology, Hôpital Universitaire La Timone, Marseille, France, 8Department of Cardiology, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, 9Antwerp University Hospital, University of Antwerp, Edegem, Belgium, 10Clínica RedSalud Vitacura and Hospital el Carmen de Maipú, Santiago, Chile, 11Department of Cardiology, Royal Melbourne Hospital and the
Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia, 12University of Birmingham Centre for Cardiovascular Sciences City Hospital, Birmingham, England, 13Mediclinic Midstream Hospital, Department Cardiology (Electrophysiology), Centurion, South Africa, 14Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; and Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark, 15University Hospital Rangueil, Cardiology, Toulouse, France, 16Cardiology Clinic, Clinical Center of Serbia, School of Medicine, University of Belgrade, Serbia, 17Service de Cardiologie, Institut Lyric, CHU de Bordeaux, Bordeaux, France, 18Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia, 19Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA, 20Service de Cardiologie et Laboratoire d'Electrophysiologie Cardiaque, Centre Hospitalier Universitaire Trousseau et Université François Rabelais, Tours, France.

Address for Correspondence:
David O. Arnar, MD PhD EMPH
Department of Internal Medicine, Division of Cardiology, Landspitali - The National University Hospital, Hringbraut, 101 Reykjavik, Iceland
davidar@landspitali.is

Abstract:
Asymptomatic arrhythmias are frequently encountered in clinical practice. Although studies specifically dedicated to these asymptomatic arrhythmias are lacking, many arrhythmias still require proper diagnostic and prognostic evaluation and treatment to avoid severe consequences, such as stroke or systemic emboli, heart failure or sudden cardiac death. The present document reviews the evidence, where available, and attempts to reach a consensus, where evidence is insufficient or conflicting.

Key words: Atrial fibrillation, arrhythmias, asymptomatic, evaluation, treatment, ventricular tachycardia, bradycardia, asystole, extrasystoles, atrial tachyarrhythmias, stroke, tachycardia induced cardiomyopathy, heart failure, Wolff Parkinson White syndrome.

Word count: 14,179 (text only)
### List of abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACC</td>
<td>American College of Cardiology</td>
</tr>
<tr>
<td>ACE</td>
<td>angiotensin converting enzyme</td>
</tr>
<tr>
<td>ACS</td>
<td>acute coronary syndrome</td>
</tr>
<tr>
<td>AF</td>
<td>atrial fibrillation</td>
</tr>
<tr>
<td>AHA</td>
<td>American Heart Association</td>
</tr>
<tr>
<td>AHRE</td>
<td>atrial high rate episode</td>
</tr>
<tr>
<td>APHRS</td>
<td>Asia Pacific Heart Rhythm Association</td>
</tr>
<tr>
<td>ARVC</td>
<td>arrhythmogenic right ventricular cardiomyopathy</td>
</tr>
<tr>
<td>AVRT</td>
<td>atrioventricular reentrant tachycardia</td>
</tr>
<tr>
<td>AV</td>
<td>atrioventricular</td>
</tr>
<tr>
<td>BP</td>
<td>blood pressure</td>
</tr>
<tr>
<td>CASSA</td>
<td>Cardiac Arrhythmia Society of Southern Africa</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence interval</td>
</tr>
<tr>
<td>CIED</td>
<td>cardiac implanted electronic device</td>
</tr>
<tr>
<td>CMP</td>
<td>Cardiomyopathy</td>
</tr>
<tr>
<td>CMR</td>
<td>Cardiovascular magnetic resonance imaging</td>
</tr>
<tr>
<td>CPVT</td>
<td>catecholaminergic polymorphic ventricular tachycardia</td>
</tr>
<tr>
<td>CRT</td>
<td>cardiac resynchronization therapy</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>EHRA</td>
<td>European Heart Rhythm Association</td>
</tr>
<tr>
<td>EPS</td>
<td>electrophysiological study</td>
</tr>
<tr>
<td>ERP</td>
<td>effective refractory period</td>
</tr>
<tr>
<td>ESC</td>
<td>European Society of Cardiology</td>
</tr>
<tr>
<td>ESUS</td>
<td>embolic stroke of unknown source</td>
</tr>
<tr>
<td>HCM</td>
<td>hypertrophic cardiomyopathy</td>
</tr>
<tr>
<td>HF</td>
<td>heart failure</td>
</tr>
<tr>
<td>HFA</td>
<td>Heart Failure Association</td>
</tr>
<tr>
<td>HR</td>
<td>hazard ratio</td>
</tr>
<tr>
<td>HRS</td>
<td>Heart Rhythm Society</td>
</tr>
<tr>
<td>ICD</td>
<td>implantable cardioverter defibrillator</td>
</tr>
<tr>
<td>ICM</td>
<td>implantable cardiac monitor</td>
</tr>
<tr>
<td>ILR</td>
<td>implantable loop reorder</td>
</tr>
<tr>
<td>LAHRS</td>
<td>Latin America Heart Rhythm Association</td>
</tr>
<tr>
<td>LBBB</td>
<td>left bundle branch block</td>
</tr>
<tr>
<td>LQTS</td>
<td>long QT syndrome</td>
</tr>
<tr>
<td>LV</td>
<td>left ventricle</td>
</tr>
<tr>
<td>LVEF</td>
<td>left ventricular function</td>
</tr>
<tr>
<td>LVOT</td>
<td>left ventricular outflow tract</td>
</tr>
<tr>
<td>MEPPC</td>
<td>multifocal ectopic Purkinje-related premature contractions</td>
</tr>
<tr>
<td>MI</td>
<td>myocardial infarction</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>NOAC</td>
<td>non-vitamin K antagonist oral anticoagulant</td>
</tr>
<tr>
<td>NSVT</td>
<td>non-sustained ventricular tachycardia</td>
</tr>
<tr>
<td>OAC</td>
<td>oral anticoagulation</td>
</tr>
<tr>
<td>PAC</td>
<td>premature atrial contractions</td>
</tr>
<tr>
<td>PM</td>
<td>pacemaker</td>
</tr>
<tr>
<td>PVC</td>
<td>premature ventricular contractions</td>
</tr>
<tr>
<td>PVS</td>
<td>programmed ventricular stimulation</td>
</tr>
<tr>
<td>RBBB</td>
<td>right bundle branch block</td>
</tr>
<tr>
<td>RCT</td>
<td>randomized clinical trial</td>
</tr>
<tr>
<td>RV</td>
<td>right ventricle</td>
</tr>
<tr>
<td>RVOT</td>
<td>right ventricular outflow tract</td>
</tr>
<tr>
<td>SCD</td>
<td>sudden cardiac death</td>
</tr>
<tr>
<td>SND</td>
<td>sinus node dysfunction</td>
</tr>
<tr>
<td>SVT</td>
<td>supraventricular tachycardia</td>
</tr>
<tr>
<td>TICMP</td>
<td>tachycardia-induced cardiomyopathy</td>
</tr>
<tr>
<td>TOF</td>
<td>tetralogy of Fallot</td>
</tr>
<tr>
<td>USA</td>
<td>United States of America</td>
</tr>
<tr>
<td>V</td>
<td>ventricular</td>
</tr>
<tr>
<td>VF</td>
<td>ventricular fibrillation</td>
</tr>
<tr>
<td>VKA</td>
<td>vitamin K antagonist</td>
</tr>
<tr>
<td>VT</td>
<td>ventricular tachycardia</td>
</tr>
<tr>
<td>WPW</td>
<td>Wolff Parkinson White</td>
</tr>
</tbody>
</table>
I. Introduction

An individual’s awareness of having an abnormal heart rhythm can be highly variable. While many patients are acutely aware of even a minor heart rhythm irregularity others may be unaware to episodes of rapid tachyarrhythmias.

Palpitations are the most common symptom reported by patients with cardiac arrhythmias of various types and duration. The term “palpitations” refers to a subjective perception of an abnormal cardiac activity, described by patients as an uncomfortable sensation of pulsation or motion in the chest and/or adjacent areas (1). Some report other symptoms, in association with a documented cardiac arrhythmia, such as fatigue, shortness of breath, dyspnoea, chest discomfort, dizziness or syncope. These symptoms are sometimes referred to as “atypical presentations” of a symptomatic arrhythmia (2).

On the other hand, some individuals with cardiac arrhythmias can be asymptomatic. Arrhythmias that may in certain cases be asymptomatic, such as atrial fibrillation (AF), incessant supraventricular tachycardias (SVT) and non-sustained ventricular tachycardias (NSVT) may, however, have important implications for patient outcomes (3-7). Asymptomatic AF can lead to stroke, asymptomatic ventricular arrhythmias can lead to sudden cardiac death (SCD) and any kind of sustained or repetitive tachyarrhythmias can possibly lead to deterioration of left ventricular (LV) function. Interestingly, in the same patient, the same type of arrhythmia can be symptomatic in some circumstances but asymptomatic in others (8).

The reasons for this variability in awareness of heart rhythm abnormalities are largely unclear. It is also not clear whether asymptomatic arrhythmias should be evaluated and managed differently than symptomatic arrhythmias. This is not least because published studies on the approach to and therapy of arrhythmias in large part only include symptomatic individuals. However, as asymptomatic arrhythmias are neither rare nor in some cases benign, there is a need for guidance on this particular topic.

Asymptomatic arrhythmias are frequent in daily practice and may in some cases considered to be more benign than symptomatic ones and not in need of treatment. However, it is important for clinicians to recognize that this is not always be true and that some asymptomatic arrhythmias may require a detailed evaluation and in certain cases, appropriate treatment. Recently there has been a rapid increase in the number of medical devices and accessories that can evaluate heart rate or even record a rhythm strip that are available directly to consumers. They have the potential to increase the diagnostic yield of heart rhythm disturbances and increase the prevalence of asymptomatic arrhythmias substantially in the coming years.

Given that the approach to asymptomatic arrhythmias is neither particularly clear or straightforward, the European Heart Rhythm Association (EHRA) in collaboration with the Heart Failure Association (HFA), the Heart Rhythm Society (HRS), the Asia Pacific (APHRS), the Cardiac Arrhythmia Society of Southern Africa (CASSA) and Latin American Heart Rhythm Society (LAHRS), convened a Task Force to review the clinical implications of specific types of
asymptomatic arrhythmias. The goal was to emphasize evidence-based approaches for risk stratification and appropriate pharmacological or non-pharmacological treatments, where evidence does indeed exist for asymptomatic arrhythmias. However, ultimately the decision on management must be made by the healthcare provider after discussion with the patient, taking into account individual factors and preferences, along with potential benefits and risks involved.

II. Preamble

Members of the Task Force were advised to perform a detailed literature review, weigh the strength of evidence for or against a particular approach, treatment or procedure, and include estimates of expected health outcomes where data exist. Patient-specific modifiers, co-morbidities, and issues of patient preference that might influence the choice of particular tests or therapies are considered, as is the need for follow-up and not least cost-effectiveness. With regard to issues without evidence other than clinical experience, a consensus was achieved by agreement of the expert panel after thorough discussions. This document was prepared by the Task Force with representation from EHRA, HFA, HRS, APHRS, CASSA and LAHRS. The document was peer-reviewed by official external reviewers representing EHRA, HFA, HRS, APHRS, CASSA and LAHRS.

Consensus statements are evidence-based when possible and derived from available published data or determined through consensus opinion where data are not available. However, the current systems of ranking level of evidence have become complicated such that their practical utility can be compromised. Therefore we opted for an easier and a more user-friendly system of ranking using ‘coloured hearts’ that should allow physicians to easily assess the current status of the evidence and consequent guidance (Table 1). This EHRA grading of consensus statements does not have separate definitions of the level of evidence. This categorization, used for consensus statements, must not be considered as directly similar to that used for official society guideline recommendations, which apply a classification (Class I-III) and level of evidence (A, B and C) to recommendations used in official guidelines.

Thus, a green heart indicates a ‘should do this’ consensus statement or indicated treatment or procedure that is based on at least one randomized trial, or is supported by strong observational evidence that it is beneficial and effective. A yellow heart indicates general agreement and/or scientific evidence favouring a ‘may do this’ statement or the usefulness/efficacy of a treatment or procedure. A ‘yellow heart’ symbol may be supported by randomized trials based on a small number of patients or results which are perhaps not widely applicable. Treatment strategies for which there is scientific evidence of potential harm and should not be used (‘do not do this’) are indicated by a red heart (Table 1).

Finally, this is a consensus document that includes evidence and expert opinions from several countries. The pharmacologic and non-pharmacologic antiarrhythmic approaches discussed may, therefore, include drugs that do not have the approval of governmental regulatory agencies in all countries.
III. Arrhythmias and symptoms

Arrhythmias may be associated with diverse symptoms, as discussed in the introduction. On the other hand, some individuals may be completely asymptomatic from their heart rhythm disturbance. It should also be clearly noted that not all individuals that experience palpitations are actually having an arrhythmia simultaneously (9). This interesting issue on symptoms or the lack of them in arrhythmias is rather poorly understood, but is likely complex and may be influenced by a number of recognized and confounding factors. In part this might be because many studies suffer from a lack of structured systematic assessments and survey instruments for symptoms. In addition there is a lack of good data assessing symptoms and arrhythmia burden. Also potential placebo and nocebo effects of therapeutic interventions are not controlled for in most studies on symptoms.

There are could be many possible contributing factors in determining whether arrhythmias might cause symptoms or not. The type and origin of the arrhythmia likely play a part in determining whether it is symptomatic or not. The presence of various cardiovascular disorders which may lead to systolic or diastolic dysfunction likely plays an important role. As such, isolated premature beats from both the atria and the ventricles and short bursts of arrhythmias might be less likely to produce symptoms than sustained episodes of the same heart rhythm abnormality. There are no data to suggest that atrial tachyarrhythmias cause fewer palpitations than ventricular tachyarrhythmias although the latter could possibly have a greater effect on blood pressure, perhaps leading to dizziness or even syncope. In tachyarrhythmias decreased diastolic filling time might contribute to a lowering of blood pressure and symptoms. The hemodynamic effect of a heart rhythm disturbance is also likely to be determined by the rate of the arrhythmia, circulating blood volume at the time of the arrhythmia, function of the left ventricle, and concurrent co-morbidities. The faster the ventricular response during the arrhythmia the more likely it is to cause symptoms and the lower the left ventricular ejection fraction, the less likely the individual is to tolerate a sustained rapid arrhythmia. There are also indications that younger individuals may have more symptoms from arrhythmias than those who are older (10). With bradyarrhythmias in general it is believed that a sinus or atrioventricular pause of at least 6-7 seconds is needed to cause symptoms such as syncope (11).

Many people who have arrhythmias also have structural cardiovascular disorders and are taking medications that can affect the ability of the heart to tolerate a heart rhythm disturbance. Such medications include beta blockers, calcium channel antagonists and various vasodilators. These drugs might accentuate a negative hemodynamic response during a tachyarrhythmia and in turn increase the probability of symptoms. They may also have an effect on chronotropic response which may also play a role in determining the degree and severity of symptoms.

Sympathetic nervous system afferents are connected to sensory mechanoreceptors which are activated by the mechanical stretch resulting from a premature ventricular contraction (12). This causes the perception of premature beats by some patients; a similar mechanism may also involve vagal afferents, also connected to mechanoreceptors, and this explains the sensation referred to the neck region by some patients. The autonomic nervous system modulates cardiac activity in a variety of ways and may in some cases have arrhythmogenic effects and facilitate the
induction of heart rhythm disturbances (13, 14). Indeed, cardiac sympathetic denervation has been used to prevent life threatening arrhythmias (15). The autonomic nervous system tone may also affect the rate, persistence and hemodynamic consequences of arrhythmias and via this mechanism possibly influence the perception of the individual’s symptoms.

Pain tolerance can vary substantially between patients and the relationship between arrhythmias and symptoms also varies greatly between patients. For example, whereas some patients with a very high burden of premature ventricular contractions (PVCs) (> 20%) are completely asymptomatic, other patients experience uncomfortable symptoms with a single PVC. It is sometimes referred to patients with a low threshold for experiencing symptoms with arrhythmias as having “cardiac awareness” (16).

The pathophysiologic basis for this significant variation in threshold for symptoms is not known. It is also unknown if genetic influences play a role in whether arrhythmias cause symptoms or not, however, cultural variations between populations, ethnicity or educational level certainly all play a role in the perception and expression of medical symptoms. There is growing evidence demonstrating an association between psychosocial factors and the risk of cardiac arrhythmias (17). The type of personality might also have an effect of the individual’s perception of the arrhythmia although that relationship has not yet been well defined.

IV. Premature atrial contractions and nonsustained atrial tachyarrhythmias.

Premature atrial contractions (PACs), while common, do not always cause symptoms and many patients with PACs may be completely unaware of their occurrence (18). It is less clear, however, what proportion of patients who experience PACs have symptoms; what demographic and clinical variables predict whether a patient has symptoms at the time of the PACs; and what is the link between the number of PACs and the development of associated symptoms?

The occurrence of symptoms in arrhythmias is an issue that has been speculated on in the previous chapter and the focus of this section will be to describe the clinical importance of PACs, regardless of whether they are symptomatic or asymptomatic. In this regard it is important to recognize that most clinical trials, which have studied the clinical impact of atrial premature beats, did not categorize atrial PACs on the basis of whether they are symptomatic or not but rather their burden over a given period (18-21). It might also be important to note that some cohorts may have an unusually heightened awareness of PACs including individuals after AF and SVT ablations.

Over the past two decades the rather common belief that PACs are benign and of little clinical importance has evolved considerably. Today, it is well recognized that the presence of frequent PACs or shorts runs of PACs may be a strong independent predictor of development of atrial tachycardia and AF (19-21). However, the impact of having completely asymptomatic PACs is currently unknown.
There have been some studies that have attempted to evaluate the risk of PACs on outcomes. In a study by Binici et al., 48-hour Holter data from the Copenhagen Holter Study, which enrolled healthy middle aged men and women, assessed the relationship between PACs and outcomes of incident AF, stroke and death (19). In this study 15% of individuals without known cardiovascular disease had excessive supraventricular ectopic activity, defined in this case as a 30 PACs burden of more than per hour. After a median follow-up time of 6.3 years excessive PACs were associated with both the primary endpoint of death or stroke (hazard ratio (HR) 1.64; 95% CI 1.03 to 2.60, p<0.036) and admissions for AF (HR 2.78; 95% CI 1.08 to 6.99, p < 0.033) (19).

Also, an increase in the number of PACs has been associated with a greater risk of both death or stroke and admissions for AF (19). In the same cohort from Copenhagen but with a longer median follow-up of 14.4 years, Larsen and coworkers found that excessive atrial ectopic activity was associated with a twofold increase in the adjusted risk of stroke (22). Interestingly, less than 15% of patients with a high number of PACs and stroke had a clinical diagnosis of AF prior to their stroke. Furthermore, the annual stroke risk in patients with excessive atrial ectopic activity in combination with a CHA2DS2-VASc score ≥2 was 2.4% per year which is similar to patients with AF and a CHA2DS2-VASc score ≥2, supporting the view that PACs burden might actually be a possible surrogate marker for AF. Similar findings were reported by Dewland et al, who examined Holter data from 1260 people without previously known AF from the Cardiovascular Health Study, and found that a doubling of the hourly PAC count was associated with an increase in AF risk (hazard ratio 1.17, 95% CI 1.13 to 1.22) and overall mortality (hazard ratio 1.06, 95% CI 1.03 to 1.09) (21).

One explanation for this observation could be that the presence of frequent PACs identifies patients likely to develop AF, and development of AF leads to an increased risk of stroke and death. A second possible mechanism for these observations is that frequent PACs alone may be a marker for a subclinical, atrial cardiomyopathy, that might promote both the development of AF and increased stroke risk (21, 23, 24). This “atrial cardiomyopathy hypothesis” proposes that the development of AF and PACs is an epiphenomenon outside the causal pathway between myopathy and stroke. Recent genetic studies showed a connection between mutations in sarcomer genes and atrial fibrillation, a link that may be mediated through a subclinical atrial cardiomyopathy (25-27).

Many questions remain unanswered concerning this link between PACs, AF, stroke, and increased mortality. One is whether treatment of patients with a high burden of PACs with antiarrhythmic medications or by means of catheter ablation reduces the risk of developing AF, thereby reducing stroke risk and decreasing mortality. Another concern is whether there is a clinically important cut-off for what abnormal PAC burden should be. Specific definitions of excessive supraventricular ectopic activity are lacking. As this question is unanswered it will also be important to do further research to define the day-to-day variability in PAC frequency and what the optimal screening test should be. At the present time, a 24-hour Holter monitor is the “gold standard” for assessing PAC frequency. According to Gladstone et al, excessive ectopic activity was felt to be present when PACs burden was >500 PACs/day are observed on Holter monitoring. The probability of AF increased from increased from less than 9% among patients...
with PACs burden <100/24 h to over 40% in those with a PAC burden of >1500/24 h) (28). In this consensus document we have chosen to accept that a high burden of PACs exists when they exceed 500 in 24 hours.

Yet another important unresolved question concerns the use of anticoagulation. It stands to reason that patients with an increased stroke risk profile who have a certain frequency of PACs could benefit from anticoagulation. However, the benefit/risk of such an approach requires testing in clinical trials. Regarding the significance of asymptomatic vs. symptomatic PAC in this setting, there is simply lack of data and knowledge.

A summary of studies on PACs and clinical consequences is provided in a table as an online supplement.

<table>
<thead>
<tr>
<th>Consensus statement</th>
<th>Symbol</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with a high PAC burden (&gt;500/24 hours) on Holter monitor should be considered at increased risk for development of AF and be educated on the symptoms of AF. They should undergo further evaluation for possible AF including more detailed monitoring.</td>
<td><img src="hearts.png" alt="green heart" /></td>
<td>(19-21), expert consensus</td>
</tr>
<tr>
<td>Comprehensive cardiovascular risk factor modification is recommended for patients with a high PAC burden including careful control of hypertension, weight loss, and screening for sleep apnea. In addition, evaluation for structural heart disease should be considered.</td>
<td><img src="hearts.png" alt="green heart" /></td>
<td>Expert consensus</td>
</tr>
<tr>
<td>When brief episodes of AF, which per se would not be an indication for oral anticoagulation (OAC), are observed, the burden of PACs (&gt; 500 PACs/24 hour or any episode of runs of more than 20 PACs) could add to the decision process regarding anticoagulation therapy or not. This decision should always be made on an individual basis.</td>
<td><img src="hearts.png" alt="yellow heart" /></td>
<td>Expert consensus</td>
</tr>
<tr>
<td>Low to moderate PAC burden without documented AF is not an indication for oral anticoagulation</td>
<td><img src="hearts.png" alt="red heart" /></td>
<td>Expert consensus</td>
</tr>
</tbody>
</table>

V. Asymptomatic ventricular pre-excitation
The prevalence of ventricular pre-excitation, also termed a delta wave or Wolff Parkinson White (WPW) pattern on an ECG, is estimated to be 0.1-0.3% (33, 34). The life-time risk of sudden cardiac death (SCD) in symptomatic WPW syndrome has been estimated at 3-4% (35, 36). Consequently, there has been a general agreement that symptoms of pre-excitation is a Class I indication for an electrophysiology study (EPS) with a view to catheter ablation of the accessory pathway.

Individuals with asymptomatic pre-excitation, however, have a lower lifetime risk of SCD and this has varied between 0 and 0.6% (35-37). The approach to individuals with asymptomatic pre-excitation is not as straightforward as in those that are symptomatic and has continued to be a hot topic of discussion over the past decades. One of the key issues debated has been whether or not to attempt to invasively risk stratify with an EPS and ablate the accessory pathway in those at perceived increased risk of sudden cardiac death. Back in 2003, the joint AHA, ACC, ESC guidelines did state that the positive predictive value of EPS was too low to justify routine use in asymptomatic patients (38). However, this topic continues is far from being resolved.

An initial evaluation of the patient with asymptomatic pre-excitation could include an exercise stress test and/or a 24-hour Holter monitor looking for accessory pathway block with increasing heart rate and intermittent accessory pathway conduction over the 24 hours. Both are indicative of a long effective refractory period (ERP) of the pathway. The individual with intermittent pre-excitation during sinus rhythm is perceived to be at very low risk for SCD.

On the other hand, high risk features for increased risk of SCD in patients with ventricular pre-excitation include a young age (39), inducibility of atrioventricular tachycardia (AVRT) during EPS (40), a short antegrade ERP of the accessory pathway (<250 ms) (39-41) and multiple accessory pathways (40, 42, 43). It has also been a study suggesting that high adrenergic states, exercise or emotion might lead to more rapid conduction over the accessory pathway (24).

A few randomized studies have been performed in attempt to evaluate the risk of sudden death in patients with suggested high-risk EPS features. In a rather small study of 73 patients none of those who had an ablation suffered AF or VF in follow-up. However, 43% of the control patients had AVRT, 14% had AF and there was 1 aborted VF in a 22-year-old male with multiple accessory pathways (44). In a similar randomized study of 60 children with high risk EPS features, during follow-up 7/27 control patients had AF and there was 1 sudden death in a patient who had first presented with AF but whose parents had declined ablation. There were no patients in whom VF was the initial presentation (45). In a recent meta-analysis, Obeyesekere et al (46), evaluated 20 studies including a total of 1869 patients with a mean age of 7 to 43 years. Ten SCDs occurred during 11,722 person-years of follow-up. In this analysis, 7 studies originated from Italy and reported 9 SCDs. The overall SCD risk was 1.25 per 1000 person-years with children having a higher risk (1.93 vs 0.86 per 1000 person-years, P=0.07). There were 156 AVRTs in 9884 person-years of follow up from 18 studies with a risk of 16 per 1000 person-years follow-up. The authors concluded that the low incidence of SCD and AVRT argued against routine EPS in most asymptomatic individuals with WPW.
Pappone et al (47), recently reported 8-year single centre registry of 2169 patients undergoing ablation for ventricular pre-excitation including both symptomatic and asymptomatic patients. In the 1001 patients who did not have ablation, VF occurred in 1.5% of patients, virtually exclusively (13 of 15) in children (median age, 11 years), and was associated with a shorter accessory pathway antegrade ERP and AVRT initiating AF but not with symptoms. In the ablation group, ablation was successful in 98.5%, and no patients developed malignant arrhythmias or VF over the 8-year follow-up. The authors concluded that the prognosis of the WPW syndrome depended on intrinsic electrophysiological properties of the accessory pathway rather than on symptoms.

Discussion on this subject has so far failed to reach a clear consensus. It is of importance in this discussion to understand that ablation can be performed with exceedingly low risk in the modern era and as an example there was only one major complication reported in the above registry in 2169 patients (29).

In a systematic review on risk stratification for arrhythmic events in patients with asymptomatic pre-excitation for the 2015 ACC/AHA/HRS guidelines on SVT it was concluded that the existing evidence suggests risk stratification with an electrophysiological study of patients with asymptomatic pre-excitation may be beneficial, along with consideration of accessory-pathway ablation in those deemed to be at high risk of future arrhythmias. Given the clear limitations of the existing data, well-designed and well-conducted studies are needed (30).

The more recent EHRA guidelines on supraventricular tachycardia suggestions are along similar lines (48). EPS for risk stratification may be considered in individuals with asymptomatic pre-excitation. We would add that this may strongly considered in those that are professional athletes or have an occupation risk such as pilots or heavy machinery operators. It may also be taken in to account that the presence of a delta wave might exclude individuals, including school children, from activities such as sports. Catheter ablation may be considered in those in asymptomatic individuals with high risk features, (antegrade ERP of the accessory pathway <240 ms, inducible AVRT triggering pre-excited AF and multiple accessory pathways). Observation without treatment may be reasonable in those with asymptomatic pre-excitation who are low risk either due to intermittent delta wave or an electrophysiology study not demonstrating high risk features.

<table>
<thead>
<tr>
<th>Consensus statements</th>
<th>Symbol</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observation may be reasonable in those with asymptomatic pre-excitation who are low risk either due to intermittent delta wave or an electrophysiology study not demonstrating high risk features.</td>
<td><img src="heart.png" alt="Heart" /></td>
<td>(49)</td>
</tr>
<tr>
<td>EPS for risk stratification may be considered in individuals with asymptomatic pre-excitation. Catheter ablation may be considered in those in asymptomatic individuals with high risk features, (antegrade ERP of the accessory pathway &lt;240 ms, inducible AVRT triggering pre-excited AF and multiple accessory pathways).</td>
<td><img src="heart.png" alt="Heart" /></td>
<td>(48)</td>
</tr>
</tbody>
</table>
VI. Atrial fibrillation and flutter

Asymptomatic AF usually refers to AF that is not associated with symptoms and incidentally discovered during routine clinical examination or detected by screening and recorded for ≥30 seconds via surface ECG method(s) (5, 30, 50) (Table 2). Compared with AF, sometimes termed subclinical AF detected via implanted devices (50, 51), AF detected by routine clinical examination or an EKG usually implies a higher arrhythmia burden sufficient to be detected using single-point or intermittent ECG/Holter/loop recorder recording (51, 52).

The true prevalence of asymptomatic AF is unknown (5, 50). Reported rates vary from 10-40%, depending on the risk profile of the evaluated cohort, monitoring intensity and follow-up duration, but a greater likelihood of asymptomatic AF has been consistently observed among the elderly, males and those with non-paroxysmal AF (2, 53-63). Symptomatic patients (especially those managed using a rhythm control strategy) may also have episodes of silent AF, particularly after AF catheter ablation (64). Indeed, in patients implanted with a cardiac monitor before ablation, a post-ablation setting was the strongest independent predictor of asymptomatic AF episodes (65). Since the absence of symptoms may be misleading, a solely symptom-based assessment of AF burden or ablation success is usually inaccurate. On the other hand, ablation of AF is in many cases used as a treatment for excessive or recurrent symptoms, in which case absence of them might in many cases be more than welcome by the patient.

Although the presence of AF symptoms may not be driven only by concomitant cardiac and non-cardiac conditions, but also by patient-related psychological and somatic factors (66, 67), available data suggest that asymptomatic AF could portend a less favorable prognosis, with greater morbidity and mortality than symptomatic AF (Table 3), possibly due to a later referral for thromboembolic risk stratification and therapeutic intervention.

Management of asymptomatic AF patients generally should be based on the same principles as if they were symptomatic (30, 68-70). An integrated approach such as the ABC pathway – Avoid
stroke with Anticoagulation (optimize stroke prevention), Better symptom management (patient-centered symptom directed use of rate or rhythm control strategies) and Cardiovascular and comorbidity risk factor management (Figure 1) summarizes key components of AF management and can help align AF management among healthcare specialties (71). While symptom management may not be acutely relevant in asymptomatic individuals with AF, steps to try to prevent longstanding AF or decrease the risk of developing tachycardia induced cardiomyopathy may be. A trial of rhythm control in asymptomatic persistent AF patients may help discern true asymptomatic from symptomatic AF. There are no randomized data on treatment effects specifically in asymptomatic AF, but benefits at least similar to those seen in symptomatic AF can be assumed (5, 30, 68).

Oral anticoagulant therapy (OAC) using either vitamin K antagonists (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban or edoxaban effectively reduces stroke, systemic embolism and mortality in AF patients at increased risk of stroke (72, 73). Compared to VKAs, NOACs exert broadly similar efficacy, but are safer with less intracranial bleeding, and more convenient for long-term use (73, 74). The decision to use OAC for thromboprophylaxis in AF patients depends on the presence of CHA₂DS₂-VASc stroke risk factors, not arrhythmia-related symptoms (30, 68, 71). In observational studies of asymptomatic AF, OAC use versus no therapy has been associated with significant reduction in stroke and mortality (75), and residual stroke risk was similar among anticoagulated AF patients and matched non-AF controls (76). Good long-term adherence to NOACs (77) may be particularly challenging in asymptomatic patients but in a study of screening detected AF, the 5-year adherence to OAC was 88% and stroke rates significantly declined (78).

Whether OAC can be stopped after an AF ablation procedure is uncertain, especially since AF recurrences are common, and may be asymptomatic. Hence current guidelines recommend continuation of OAC in the presence of stroke risk factors, irrespective of the apparent success of rhythm control interventions (79). The OCEAN trial is an ongoing multicentre randomized controlled trial evaluating two antithrombotic treatment strategies (rivaroxaban vs. aspirin) for patients with risk factors for stroke after apparently successful AF ablation (80).

With the greater availability of screening tools, asymptomatic individuals will be increasingly diagnosed with paroxysmal AF that would be missed by a routine ECG/Holter recording (5, 50, 78). The incremental burden of AF, reflected by the clinical types of AF (from paroxysmal, to persistent and to permanent AF), has been associated with increasing risk of stroke in post-hoc analyses of randomized clinical trials (81-89), AF registries (90-93) and a meta-analysis of 12 studies (94). Although generally lower in paroxysmal compared to non-paroxysmal AF (Figure 2A-B), the annual stroke rates among non-anticoagulated patients with paroxysmal AF and ≥1 CHA₂DS₂-VASc stroke risk score (81-83) (Figure 2A) is sufficiently high to merit OAC use (30, 68). Of note, major bleeding rates among anticoagulated AF patients were broadly similar across AF types (84-87, 94) (Figure 2C). Incremental AF burden has been also associated with increased risk of tachycardia-induced cardiomyopathy (95, 96), heart failure (58, 97-100), cognitive impairment/dementia (101, 102) and mortality (84-87, 94).
Asymptomatic AF has been independently associated with greater risk of progression than symptomatic arrhythmia (HR 1.6, 95% CI 1.1-2.2) (58). Five and ten years after detection, paroxysmal/persistent asymptomatic AF progressed to permanent in 25% and 50% of patients, respectively (58, 78). Increasing evidence shows that comprehensive risk factor management (e.g., blood pressure lowering (103-105), weight reduction (106-108), glucose control (109), treatment of obstructive sleep apnea (110)) and lifestyle modification (e.g., physical exercise and cardiorespiratory fitness (111-114), stress management (115, 116)) could decrease the burden of AF (117-119). These interventions have not been investigated specifically in asymptomatic AF patients, but their benefits would likely be similar to those seen in symptomatic patients (120).

A decrease in AF burden after successful AF catheter ablation could reduce the risk of major AF-related outcomes including heart failure, stroke and mortality, as suggested by many observational studies evaluating mostly highly symptomatic patients (121-135). However, observational data have numerous limitations (136), and undertaking AF ablation to abolish the need for long-term OAC is presently not recommended (30, 68, 137). The effects of rhythm control using AF ablation are currently being explored in several ongoing randomized outcome studies (e.g., CABANA [NCT00911508], EAST [NCT01288352], OAT [01959425]).

In the CASTLE-AF randomized study, AF ablation yielded a 47% mortality rate reduction compared with conventional rhythm control among symptomatic anticoagulated AF patients with heart failure treated with an implantable defibrillator (predominantly middle-aged males with moderate left ventricular dysfunction) over a median 3-year follow-up (138). In the CABANA trial, there was no significant difference between catheter ablation compared to medical therapy for the primary outcome of composite of death, disabling stroke, serious bleeding, or cardiac arrest, although symptoms were improved in the ablation arm (139).

Whether (and how) asymptomatic AF patients would benefit from AF ablation still needs to be fully established. Incidental diagnosis of AF may trigger symptoms in susceptible patients as they become aware of a heart condition (140), and even failed AF ablation may have a placebo effect in such patients (141). A challenge with rhythm control (e.g., using electrical cardioversion) could identify apparently asymptomatic patients who had subconsciously adapted to AF by restricting their lifestyle or have atypical symptoms (137, 140). In many cases a trial with an anti-arrhythmic drug might considered after cardioversion before considering ablation. Whereas these patients would likely experience symptomatic improvement after successful AF ablation (141), a failed procedure may turn truly asymptomatic patients into symptomatic due to post-procedural atrial tachyarrhythmias (such scenario has been reported in 24%-34% of patients) (142, 143). The decision to use AF ablation in asymptomatic patients should be a shared informed process that considers not only potential benefits (pending further evidence from randomized studies), but also the risk of serious procedure-related complications (≤4%) and patient’s values and preferences for treatment and outcomes (66) (Figure 1). Notwithstanding that the exact AF duration before diagnosis is difficult to establish in asymptomatic patients, consideration of AF ablation in such patients may be considered in selected younger patients with paroxysmal or persistent (but not long-term persistent) AF (Class IIb, Level of evidence C) (137).
As for atrial flutter, a lot of what has been said for AF also applies to this arrhythmia. While the risk of thromboembolism is slightly less, the same indications exist for anticoagulation. Atrial flutter has however been studied a lot less than AF. Very little is known specifically about asymptomatic atrial flutter but treatment options would include initial rate control and consideration of cardioversion and/or ablation.

<table>
<thead>
<tr>
<th>Consensus statements</th>
<th>Symbol</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with asymptomatic AF should be anticoagulated, according to their calculated risk of stroke, equal to patients with overt AF.</td>
<td>🚨</td>
<td>(69, 70, 144, 145)</td>
</tr>
<tr>
<td>Consideration should be given to screening high risk individuals e.g. with a CHA2DS2-VASc score ≥ 2 for atrial fibrillation.</td>
<td>🚨</td>
<td>Expert opinion</td>
</tr>
<tr>
<td>Lifestyle changes should be advised in patients with asymptomatic AF, equally to patients with overt AF.</td>
<td>🚨</td>
<td>(69, 70, 144, 145)</td>
</tr>
<tr>
<td>Cardioversion of persistent AF in asymptomatic patients may be advised to differentiate between truly asymptomatic patients or those adapted to AF related symptoms.</td>
<td>🚨</td>
<td>(79, 140)</td>
</tr>
<tr>
<td>Rate control drugs should be prescribed to patients with asymptomatic AF with fast AV conduction in order to attempt to decrease risk of tachycardia induced cardiomyopathy.</td>
<td>🚨</td>
<td>(95, 96)</td>
</tr>
<tr>
<td>Ablation might be proposed to selected patients with asymptomatic AF, based on patient’s preferences, after detailed informed consent.</td>
<td>🚨</td>
<td>(79) + expert opinion</td>
</tr>
</tbody>
</table>

**VII. Atrial high rate episodes**

Atrial high rate episodes (AHRE), also termed subclinical AF, are different from symptomatic or asymptomatic AF essentially by the way they are observed. The definition of AHRE varies slightly from study to study (6, 144, 146) . In the ASSERT study AHRE was defined as episodes of at least 5 minutes of atrial rate >180 bpm, detected by the continuous monitoring by cardiac implantable electronic devices (CIEDs) (50), while an episode lasting at least 30 seconds on an ECG with irregular RR intervals with no discernible, distinct P waves clinically defines AF. This can be either
in the presence (overt AF) or absence (asymptomatic AF) of symptoms typically associated with AF (i.e. palpitations, shortness of breath, lightheadedness, chest pain, pre-syncope or syncope).

Both AHRE and AF can thus be asymptomatic. Contrary to asymptomatic AF, which can be diagnosed in any patients using any kind of diagnostic tool (ECG, Holter monitoring, event recorder, implantable loop recorder), AHRE are only diagnosed in patients with CIEDs, and various algorithms from different manufacturers can detect these AHRE albeit with variable accuracy. Not all implanted devices are able to document AHRE providing intracardiac electrograms. The positive predictive value of various atrial rate and episode length was tested in the ASSERT population (147). Inappropriate detection of AHRE by counters review only was found in 10 to 17% of the > 6 min episodes and 1 to 2 % of the > 24 hours episodes. To what extent AHRE can be considered as an early stage of AF is not known. Not all patients with AHRE will develop documented AF (148). In the ASSERT study AHRE <24 hours were not associated with an increased risk of stroke (149). It needs to be emphasized that there was a temporal discordance between AHRE and strokes (146), which is begs the question of whether AHRE are causal or perhaps a risk marker of an atrial cardiomyopathy as discussed in the section on PACs. It should also be noted that in ASSERT strokes were classifies as ischemic or not but not further classified according to subtype. Thus it was not a mechanistic study in the sense that cardioembolic strokes were specifically identified.

The prevalence of AHRE in patients with CIEDs has been reported to range between 30 to 60% (150). The TRENDS study showed a doubling of risk of thromboembolic events in the presence of >5.5 hours AHRE over a 30-day period (151). The ASSERT trial detected AHRE in 10.1% of patients over the first 3 months after pacemaker implantation (146). In these patients with AHRE, the risk of developing overt AF was 5.6 times higher (95% CI 3.78-8.17, p<0.001) and the embolic risk was 2.5 times higher (95% CI 1.28-4.85, p=0.007) over a 2.8 years follow-up period. This increased stroke risk, stratified according to the CHADS2 score, was however smaller than expected in patients with comparable CHADS2 scores with overt AF: an annual stroke risk of 0.6% for AHRE vs. 2.8% for AF in CHADS2=1 patients, 1.29% for AHRE vs. 4.0% for AF in CHADS2=2 patients, and 3.8% for AHRE vs. >5.9% for AF in CHADS2 ≥3 patients (152). As mentioned previously, there was no temporal relationship between stroke and AHRE (153). Longer episodes of AHRE (>24 hours) were most associated with increased risk of ischemic stroke or systemic embolism (149).

The only published study assessing anticoagulation of patients diagnosed with AHRE was the IMPACT trial, in patients with remote monitoring of ICDs or cardiac resynchronization therapy (CRT), without history of stroke or documented AF (154). There was no difference in primary outcomes (stroke, systemic embolism, major hemorrhage, mortality) between the intervention and control arms when oral anticoagulation was decided according to the CHADS2 score. So it should be emphasized that there is no data yet to indicate whether anticoagulation for short AHREs is beneficial. The ARTESIA and NOAH-AFNET 6 trials are currently ongoing to test the effect of NOACs in CIED patients with 6 minutes to 24 hours of AHRE and with additional risk factors, but without documented AF (155, 156). The results of these studies are expected in 2021. No studies to date have suggested any benefit of any rhythm control strategy, including any antiarrhythmic drug or ablation, in these asymptomatic patients.
<table>
<thead>
<tr>
<th>Consensus statements</th>
<th>Symbol</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with AHRE have a higher stroke risk compared with patients without AHRE.</td>
<td></td>
<td>(149, 153)</td>
</tr>
<tr>
<td>The benefit of anticoagulating patients with AHRE and additional stroke risk factors, but without overt AF, is still unclear. Patients with AHRE should be referred for further investigations in order to document AF before anticoagulation is initiated. The benefit of anticoagulating patients with AHRE and additional stroke risk factors, but without documented AF, is still unclear. Patients with AHRE should be referred for further detailed evaluation unless already confirmed by stored electrograms.</td>
<td></td>
<td>(155, 156) + Expert consensus</td>
</tr>
<tr>
<td>Anticoagulation might be considered on an individual basis in those with AHRE and a CHA2DS2-VASc score ≥ 2</td>
<td></td>
<td>Expert consensus</td>
</tr>
<tr>
<td>AHRE <em>per se</em> do not require antiarrhythmic treatment</td>
<td></td>
<td>Expert consensus</td>
</tr>
</tbody>
</table>

**VIII. Premature ventricular contractions**

Isolated premature ventricular contractions (PVCs) are a normal occurrence in most individuals. A few to multiple PVCs can be seen on most 24-hour Holter monitors, including those from healthy young individuals (157). These PVCs usually originate from different locations in both right and left ventricles. They may result from focal activity or, less likely, be due to a (micro) re-entrant mechanism. In some individuals, a higher number of PVCs may be present. Frequent PVCs may be a marker for underlying abnormal substrate. This may be the result of underlying electrical, ischemic or structural alterations, leading to enhanced automaticity (e.g. in chronically ischemic tissue), triggered activity (e.g. in long-QT syndrome, or by drugs such as digoxin), or re-entrant mechanisms (e.g. in post-infarction patients).

Underlying cardiac disease is a prognostically unfavourable marker in asymptomatic patients with PVCs and requires a specialist approach to address the potential prognostic impact. PVC characteristics, such as a high burden, a more complex presentation (e.g. couplets, triplets or non-sustained runs), multifocal origin, and/or increasing PVC frequency with exercise, should all alert to potential underlying electrical, ischemic or structural alterations that may be associated with the undesired outcome of major ventricular arrhythmias or sudden death (Table 4) (158, 159). There is no absolute threshold of the number of PVCs that can be used as a cut-off for underlying disease, and hence should trigger further investigations. A study in apparently healthy
athletes has shown that in those with >2000 PVC per day, there was a 30% risk of finding underlying heart disease (160). Even in the absence of demonstrable underlying disease, a moderate to high burden of PVCs are a marker for all-cause and cardiovascular mortality, indicating that continued follow-up may be warranted (161).

The morphology of the PVCs can provide important additional information in this diagnostic conundrum, since some predilection sites of benign PVC ectopy are well recognised. The most prevalent entity in this respect are PVCs originating from the ventricular outflow tract regions, showing a clear inferior axis with high voltages in the inferior limb leads (usually with a combined amplitude of >4.5 mV of the QRS complexes in leads II, III and aVF). Most frequently, these PVCs originate from the right ventricular outflow tract (RVOT), in which case they have a left bundle branch morphology in V1 (i.e. a dominant negative QRS complex), with transition between V3 and V4. Earlier transition, and certainly when V1 shows a right bundle branch morphology, suggests a left-sided origin (which may be within the coronary cusps of the aorta, or in the endocardium or epicardium of the left ventricular outflow tract (LVOT) (162). These PVCs are thought to be the result of triggered activity, i.e. a local cellular cause which in most cases has no serious prognostic implications. Therefore, the PVCs are usually strictly unifocal, but slight morphological changes are often seen, attributed to different exit points of the ectopic activity. Although these RVOT/LVOT arrhythmias usually occur in structurally normal hearts, they may rarely be an atypical expression (forme fruste) of arrhythmogenic (right) ventricular cardiomyopathy (163).

The absence of imaging abnormalities on an echocardiogram and cardiac MRI can help to rule out structural heart disease in such patients. The demonstration of PVCs of differing morphologies from the right ventricle (RV) in patients with normal left ventricular (LV) function should prompt investigations to rule out arrhythmogenic cardiomyopathy with right ventricular dominance or sarcoidosis (164). Similarly, multifocal PVCs of LV origin should trigger investigations for non-ischemic cardiomyopathy.

Other less common locations of focal PVC are around the mitral or tricuspid annulus. These PVCs are strictly unifocal again but have a superior axis with LBBB or RBBB morphology. Locations away from the annulus are usually related to PVC originating from the His-Purkinje system. Finally, intramyocardial foci may occur, often related to the papillary muscles or the moderator band (165). Some of these foci may present with a pattern of parasystole, indicating poor electrical coupling with the surrounding tissue, or generate non-sustained ventricular tachycardia (VT). A strict unifocal presentation in the absence of demonstrable structural heart disease points to a benign automatic focus in such situations.

Very rarely, otherwise ‘benign’ PVCs may give rise to polymorphic VT or VF due to their short coupling interval (159). Short coupled PVCs impinging on the T wave may induce polymorphic VT/VF in a setting of ischemia, electrolyte abnormalities, underlying long QT syndrome (LQTS) or early repolarization syndrome. This may also rarely occur in a “normal” heart, sometimes called ‘short-coupled form of torsades de pointes’ (160). Often, such PVCs arise from the Purkinje network, but also other foci have been described. In such patients, the malignant electrical
presentation mandates aggressive treatment, possibly by ablation. In some, an implantable defibrillator may be indicated.

Frequent PVCs (usually defined as >10-15% of the total number of beats per 24 hours) can impair LV function (PVC-induced cardiomyopathy) which may be reversible with medical treatment or catheter ablation of the extrasystoles and standard therapy for the cardiomyopathy (166, 167). However, it is well recognized that not all patients with frequent PVCs will develop LV dysfunction. Factors associated with the development of LV dysfunction include: longer PVC QRS duration, epicardial PVCs, retrograde atrial activation of PVCs and interpolation of PVCs (168-170). The PVC burden remains one of the strongest predictors for the development of a PVC-induced cardiomyopathy, although the burden associated with cardiomyopathy varies between studies. Most studies are limited by a strong referral bias in enrolling patients who are symptomatic and referred for catheter ablation. The prevalence of LV dysfunction in these studies ranged from 7-52% (Table 5).

Asymptomatic patients with frequent PVCs are under represented in these studies. With these inherent limitations, there appears to be an increase in risk in the development of PVC-induced cardiomyopathy with a PVC burden >10%. However, PVC-induced cardiomyopathy has been reported in individuals with a PVC burden <10% (171, 172). A recent study measuring subtle degrees of left ventricular impairment by using speckle tracking echocardiography (measuring left ventricular global longitudinal strain and mechanical dispersion) showed mild impairment of myocardial function with a PVC burden > 8% (173). The wide range reported in studies may be partly explained by the single-day Holter monitoring used. A wide daily variation in PVC burden is well recognized. Longer monitoring has been shown to double the identification of patients with a PVC burden of >10% (174). It can be difficult to determine if the PVCs are the cause or the consequence of LV dysfunction.

Two studies have reported the natural history of PVCs. Niwano et al followed 239 consecutive patients (mostly asymptomatic) with a PVC burden >1%, with normal baseline LV function, over a mean follow-up of 5.6 years (175). Patients were grouped into those with a high, moderate and low PVC burden. Forty six patients had a high PVC burden (>20%), 105 a moderate burden (5-20%) and 88 patients had a low PVC burden (1-5%). Thirteen patients (5%) developed LV dysfunction (defined as a fall in LVEF by at least 6%) at follow-up. Patients with a high PVC burden >20% were more likely to develop LV dysfunction but this change in LVEF occurred very slowly over several years with no reported major adverse cardiac events. Dukes et al followed 1139 elderly (>65 years) patients from the Cardiovascular Health Study who had Holter monitoring and were followed up with an echocardiogram five years later and for incident heart failure (176). They reported that a PVC burden in the upper quartile (roughly equivalent to >100 PVC/24h) had a three-fold increase in the risk of incident heart failure compared to the lowest quartile. The population attributable risk of developing heart failure due to PVCs was 8.1%.

The risk of developing a PVC-induced cardiomyopathy rises with increasing PVC burden. Subtle degrees of LV dysfunction can be seen with a PVC burden as low as 8%. In studies where patients were referred for management of PVCs, usually because of symptoms, the predictive PVC burden
to cause a PVC-induced cardiomyopathy is >10%, usually >20%. However, the vast majority of patients with frequent PVCs >10% will not go on to develop a cardiomyopathy. Studies from Niwano et al and Hasdemir et al., suggest a prevalence of 5-7% for patients with a PVC burden >10% (175, 177). Recently, the study by Dukes et al suggested the prevalence of heart failure due to PVCs in the elderly population may be higher than previously reported (176).

A proposed scheme to evaluate patients with more than expected PVC is shown in Figure 3. Although Dukes et al (176) had described a cut-off of ±100 PVCs/24h, we would suggest setting the bar at >500 PVCs to trigger an extensive work-up for underlying disease, given the findings in athletes with a 2000 PVCs/24h cut-off (160). Since excluding underlying disease is a cumbersome task, there is no defined set of ‘minimal investigations’, but conceptually three axes of evaluation need to be explored (imaging, electrical and genetic) based on what may be clinically indicated. If the evaluation is negative in an asymptomatic subject, treatment is not required but it seems reasonable to perform serial measurements of LV function (yearly) in patients with a PVC burden >10%. In patients who develop symptoms, or who have or develop LV dysfunction, medical therapy (beta-blockers, calcium blockers with or without anti-arrhythmic drug therapy) and/or catheter ablation is indicated.

There are a number of considerations to take into account when deciding whether to treat asymptomatic PVCs. In the CAST study, suppression of PVCs by flecainide and encainide after myocardial infarction was harmful (178). In cases where patients have frequent PVCs but in the background of longstanding remodeled cardiomyopathy (eccentric with thinning) or with large, dense STEMI scars, the likelihood of benefit of intervention to improve LV function may be low.

<table>
<thead>
<tr>
<th>Consensus statements</th>
<th>Symbol</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic patients with frequent PVCs (&gt;500 per 24 hours) should be referred to a specialist for further evaluation to rule out any underlying structural, ischemic or electrical heart disease.</td>
<td><img src="heart.png" alt="Heart" /></td>
<td>(158, 159)</td>
</tr>
<tr>
<td>Very frequent PVCs (burden&gt;20%) are a marker of all-cause and cardiovascular mortality and may justify intensified follow-up.</td>
<td><img src="heart.png" alt="Heart" /></td>
<td>(161)</td>
</tr>
<tr>
<td>PVCs should be treated in patients with suspected PVC-mediated cardiomyopathy</td>
<td><img src="heart.png" alt="Heart" /></td>
<td>Expert consensus</td>
</tr>
<tr>
<td>Treatment of patients with asymptomatic PVCs should focus on the underlying heart disease in order to improve prognosis</td>
<td><img src="heart.png" alt="Heart" /></td>
<td>Expert consensus</td>
</tr>
</tbody>
</table>
IX. Ventricular tachycardia

The definition of NSVT constitutes three or more consecutive ventricular beats at a rate of greater than 100 beats/min with a duration of less than 30 seconds. The prevalence of asymptomatic NSVT varies from 0.7% (healthy army population) to 10% (in a geriatric population) in patients without known heart disease (179-181). On the other hand, it is common in ischemic heart disease (30–80% of patients) during long-term ECG monitoring where it is usually asymptomatic (182).

Mode of discovery of VT may vary but a 12-lead ECG during arrhythmia should be obtained whenever possible. Whereas NSVT may be asymptomatic, sustained VT is much more often symptomatic. Slow VT, generally slower than 150 bpm, may however be asymptomatic. When lasting for hours/days individuals with slow VT may become symptomatic because of heart failure symptoms.

Definitions of different sub-types of VT are summarized in Table 6. Among ventricular arrhythmias, two distinct entities require specific mention; bidirectional VT and torsades de pointes VT. Bidirectional VT may be asymptomatic. The classic causes are digitalis toxicity or channelopathies such as catecholaminergic polymorphic ventricular tachycardia (CPVT) or Andersen-Tawil syndrome. Torsades de pointes VT is a type of VT seen exclusively in the setting of prolonged QT interval whether it is acquired or congenital.

The goal of evaluation is to try to identify an underlying structural or electrical cardiac disease and rule out underlying heart disease, primarily coronary artery disease. Suggested first- and second-line evaluations are presented in Table 7. First line investigations include clinical evaluation associated with a 12 lead ECG, rhythm monitoring (e.g., Holter monitor), echocardiogram, laboratory testing with or without an exercise stress test depending on the situation. Second line investigations may include coronary artery angiography, cardiac MRI /CT scan to rule out subtle heart disease such as focal cardiomyopathy due to ARVC. Pharmacological testing may be considered in the absence of structural heart disease to evaluate for an inherited arrhythmic disorder. This may include ajmaline and if not available flecainide testing to uncover Brugada syndrome (183). Other types of pharmacological testing such as epinephrine for diagnose LQTS (184) and isoproterenol for diagnosis of arrhythmias in ARVC have been described (185). However, epinephrine and isoproterenol testing for ventricular arrhythmias carry a risk of inducing life-threatening ventricular arrhythmias and should only be done by experts under optimal circumstances. Genetic testing may also be proposed but should be performed on careful clinical indications and preferably in dedicated centres with the experience to interpret results and with the ability to provide genetic counselling. The use of signal-averaged ECG has diminished but might be considered in special circumstances.

Management of asymptomatic ventricular arrhythmias largely depends on whether structural heart disease is present or not. In individuals without structural heart disease, non-sustained and
sometimes repetitive idiopathic VT are usually adenosine-sensitive, based on cAMP mediated triggered activity, often aggravated by exercise or emotional stress. They mainly originate from the right or left ventricular outflow tract, although there are exceptions (186-188). Rarely, verapamil-sensitive fascicular VT presents as non-sustained salvos (189-192).

Prognosis is usually considered benign in those that have no clear heart disease (180, 193), although some cases of sudden death have been described, possibly reflecting undetected cardiomyopathy or channelopathy (194). However, when asymptomatic, some patients with very frequent or incessant NSVT may develop tachycardia-induced cardiomyopathy over time (195). Pending symptoms or alteration in ventricular function, observation with no specific therapy is perfectly acceptable, although follow-up is mandatory.

Polymorphic NSVT in the absence of heart disease or channelopathy is unusual but requires detailed evaluation and in most cases treatment. Malignant polymorph VT is extremely rare in asymptomatic patients, with premature beats triggering polymorphic VT usually arising from the right ventricular outflow tract or the Purkinje network (196) with, but not always, short coupling intervals (197, 198). In those patients who are asymptomatic, the possibility of quinidine, ablation and/or ICD should be discussed with expert electrophysiologists after elimination of reversible causes.

In patients with structural heart disease, the presence of asymptomatic arrhythmias usually is a more ominous sign. No antiarrhythmic drugs, except beta-blockers, have been shown to decrease in mortality in patients with asymptomatic ventricular arrhythmia and structural heart disease. Optimal medical therapy including beta-blocker, ACE inhibitors +/- mineralocorticoid receptor antagonist is the first step. After ruling out acute coronary artery stenosis, an ICD is indicated for sustained VT without reversible cause with LVEF <35%. However, in case of mild structural heart disease with LVEF >40% and well tolerated VT, VT ablation alone has sometimes been proposed in ischemic cardiomyopathy (199) and ARVC (200). This, however, needs to be determined on a case by case basis.

Table 8 summarizes the treatment for asymptomatic patients with NSVT depending on the underlying substrate. NSVT in an asymptomatic patient with a LVEF ≥ 40% does not usually require specific antiarrhythmic therapy, but optimization of the treatment of the underlying heart disease (201). However, the prognostic value of an EP study in patients with ischemic cardiomyopathy and a LVEF >40% is currently being investigated (202). Despite the high rate of sudden death after myocardial infarction among patients with a low ejection fraction, implantable cardioverter–defibrillators are generally not indicated until 40 to 90 days after myocardial infarction. Surprisingly, the results of the recent VEST trial showed that among patients with a recent myocardial infarction and an ejection fraction of 35% or less, the wearable cardioverter–defibrillator did not lead to a significantly lower rate of the primary outcome of arrhythmic death than control (203).

In patients with left ventricular assist devices, VT is common (204) and may be well-tolerated because of the preserved cardiac output from the device. However, VT episodes seem linked to
higher mortality (204) and may suppress right ventricular function. Therefore, ablation may be considered in case of frequent VT episodes (205).

Detailed management of asymptomatic patients with channelopathies is a topic that exceeds the purpose of this paper and can be found in dedicated consensus documents (7, 206). A brief summary is found in table 9 but a few points warrant mention. When the QTc interval is prolonged an assessment of why this has occurred is necessary. Medications are not infrequent causes of QT prolongation. If a patient is taking a potential QT prolonging drug it is important to verify that there has indeed been a further prolongation of the QT interval after the medication was started because sometimes it is minimal and drug withdrawal in certain cases could be even more damaging. If drug-induced QT prolongation and electrolyte disturbance such as hypokalemia have been ruled out, consideration should be given to genetic testing for further diagnosis.

Asymptomatic non-sustained polymorphic VT in patients with Brugada syndrome or early repolarization should be considered a potentially malignant event and be managed accordingly (183). Syncope in individuals with Brugada ECG pattern who have not been diagnosed with ventricular arrhythmias might be an ominous sign while there are of course many other potential reasons for syncope in these patients. Syncope in this population should lead to a very detailed evaluation and careful consideration of treatment. However monomorphic NSVT (particularly originating from the RVOT) may sometimes be recorded and may not convey an increased risk. The management of such patients should, if possible, be discussed with an electrophysiologist, who is an expert in Brugada syndrome.

Currently, it is unknown if the few asymptomatic patients with multifocal ectopic Purkinje-related PVCs with preserved LV function may benefit from quinidine (207), with SCD only being described in patients with altered LVEF. Patients with Andersen-Tawil syndrome are often asymptomatic despite presenting with frequent salvos of VT, often bidirectional, and may be incessant (208). Rate of malignant events seem to be low on beta-blockers even if they are not directly effective in decreasing the VT burden. Flecainide seems effective against VT when combined to beta-blockers. Catheter ablation does not seem to be an option in these patients (208).

The occurrence of VT in athletes, even when asymptomatic, should lead to a thorough evaluation to eliminate the possibility of structural heart disease or the use of illegal and/or performance enhancing substances. An echocardiogram, cardiac MRI and exercise test should all be considered. Once these possibilities have eliminated, it is well recognized that intense physical activity may not only induce VT (209) but also exercise-induced arrhythmogenic RV remodeling (210). Sports induced PVCs and VTs were in a recent paper not associated with adverse events in athletes without structural heart disease (209). Interruption of physical activity lead to long-term resolution of exercise-induced VT, but athletes with persistent VT may be considered candidates for ablation to permit return to competitive sports (209).

However, a word of caution is warranted in this situation as individuals with CPVT, who usually have structurally normal hearts, may present with exercise induced VT that could be the first sign
of high risk for sudden death. Similarly, patients with an asymptomatic myocarditis would not always qualify for structural heart disease and they are known to die suddenly during exercise. This underscores the importance of a careful evaluation in these individuals. VT associated with an isolated sub-epicardial right ventricular outflow tract scar can be found in high-level endurance athletes without any evidence of ARVC, and this can be successfully treated by ablation with excellent outcomes (210).

While PVCs are common during pregnancy, VT and SCD are exceptionally rare (211). Asymptomatic VT in pregnant women with a healthy heart may in most cases be monitored without specific therapy. In cases of pregnancy induced cardiomyopathy and asymptomatic VTs a temporary use of a life vest might be considered.

In infants without any cardiac abnormality, asymptomatic ventricular arrhythmias are rare and often resolve during the first year. Left ventricular dysfunction may be due to asymptomatic VT or frequent PVCs and is reversible when the burden is decreased (212). No benefit of any anti-arrhythmic drug has been shown (213) in this situation in asymptomatic children with a normal heart.

Individuals with congenital heart disease may have a variety of arrhythmias, both symptomatic and asymptomatic. In patients with tetralogy of Fallot (ToF), the risk related to NSVT is debated (214, 215). An EP study may be proposed in case of NSVT (201). An ICD is a Class Ila indication in ToF patients presenting with other risk factors, and a Class IIb indication in patients with advanced single or systemic right ventricular dysfunction in association with other risk factors, according to the 2015 ESC Guidelines on Ventricular Arrhythmias and Prevention of Sudden Cardiac Death (7).

NSVT are common in patients undergoing chronic dialysis but mostly unrelated to SCD in this population (216, 217); thus, no therapy is recommended. Chemotherapeutic agents (mainly anthracyclines, but also other drugs such as melphalan) may acutely promote VT or torsades de pointes by different mechanisms, even in those without identifiable underlying heart disease (218, 219). Due to the risk of SCD, chemotherapy should be postponed in case of asymptomatic VT, until necessary decisions have been made about cessation or continuation of the drug together with adapted preventive therapy.

Ventricular arrhythmias are sometimes seen during rhythm monitoring during general anesthesia. In this particular situation it is very important to obtain a tracing of the arrhythmia. VT under these circumstances should lead to complete evaluation as mentioned above and in table 7 should be performed. If normal, there is no need for treatment.

Asymptomatic accelerated idioventricular rhythm may be observed in adults and children without structural heart disease (220, 221). It does not convey any increased risk of SCD and therefore, no therapy or monitoring is needed.
Patients with asymptomatic NSVT should be referred for careful evaluation to detect any underlying structural, ischemic or electrical heart disease.

<table>
<thead>
<tr>
<th>Consensus statements</th>
<th>Symbol</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with asymptomatic NSVT should be referred for careful evaluation to detect any underlying structural, ischemic or electrical heart disease.</td>
<td>![Heart symbol]</td>
<td>Expert consensus</td>
</tr>
</tbody>
</table>

**X. Tachycardia induced cardiomyopathy**

Both supraventricular and ventricular arrhythmias can lead to tachycardia-induced cardiomyopathy (TICMP) (Table 10). TICMP may be divided into two types: 1) pure, where tachycardia is the sole mechanism of worsening of left ventricular (LV) function; and 2) mixed, or impure as it was originally termed, where tachycardia worsens a pre-existing cardiomyopathy due to a different cause (195). However, the fact that pure TICMP may develop with variable incidence and severity in different patients with a similar fast heart rate over a similar duration raises the question that a latent cardiomyopathy or an underlying myocardial susceptibility could play a role in the development of TICMP.

Several studies in both animal models and in humans have suggested possible pathophysiological mechanisms for the development of TICMP (Table 11), although the understanding of this entity remains largely unclear. Overlap of the mechanisms leading to TICMP may vary in the different types of arrhythmias and their presentations. In patients with AF, the restoration of sinus rhythm results in significant improvements in ventricular function, particularly in the absence of ventricular fibrosis on cardiac MRI (222).

There are no firm diagnostic criteria for TICMP. In patients presenting with new onset LV dysfunction and a chronic or recurrent tachycardia with a heart rate >100 beats per minute, the diagnosis of TICMP may be suggested by the elements listed in Table 12 (32). Due to the retrospective nature of the diagnosis, it is often difficult to confirm a diagnosis of TICMP which can also be made by default after exclusion of other causes of worsening ventricular dysfunction. The dilemma in clinical practice is to differentiate TICMP from other forms of dilated cardiomyopathy that may be associated with atrial or ventricular arrhythmias.

Assessment of heart failure patients with a suspected tachycardia etiology should include ECG, to evaluate the cardiac rhythm and look for signs of myocardial ischemia, while an echocardiogram should be conducted to determine LV structure, functional characteristics, and to exclude valvular and pericardial abnormalities. A Holter monitor should be considered in the event of the tachyarrhythmia being paroxysmal. Evaluation of coronary arteries (by non-invasive methods or invasive coronary angiography) is necessary to rule out a potential ischemic etiology of the ventricular dysfunction. Cardiac MRI (CMR) imaging can rule out a ventricular scar, shed light on myocarditis and some specific etiologies of cardiomyopathy, and myocardial biopsy is currently rarely used in this setting (32, 223, 224).
Atrial fibrillation, the most prevalent sustained cardiac rhythm disorder, is considered the most common cause of TICMP (225, 226) in adults whilst permanent junctional reciprocating tachycardia is the most common arrhythmia associated with TICMP in children. The incidence of TICMP is variable depending upon the type of tachycardia. In a study of 625 patients referred for radiofrequency ablation of various tachyarrhythmias, TICMP was found in 17 (2.7%; 1.3% with atrial fibrillation or flutter, 0.5% with other SVT, 1% with PVCs) patients (226). The incidence for specific arrhythmias has been described as ranging from 10% in patients with focal atrial tachycardia to 25% in patients with permanent atrial flutter and 20–50% in patients with paroxysmal AVRT (32, 227, 228). Patients with rapid paroxysmal tachycardia are more likely to be symptomatic and be diagnosed sooner than those with slower, but incessant tachycardias. Identified predictors of TICMP in patients with frequent supraventricular arrhythmia or PVCs are listed in Table 14 (169, 171, 229-231).

TICMP usually resolves with treatment of the arrhythmia. The time course of improvement in LVEF is variable due to possible persistent ultrastructural changes. Some patients with TICMP may be at increased risk for sudden cardiac death after apparent improvement, which could be due to persistent myocardial fibrosis (232). Treatment goals for patients with TICMP are to slow the heart rate or reduce extrasystoles, relieve symptoms, prevent hospitalization and improve survival. Management of TICMP comprises evidence-based treatment for heart failure (HF) with reduced LVEF, including angiotensin converting enzyme inhibitors and beta-blockers and aldosterone receptor antagonists, which are fundamentally important in modifying the course of systolic HF (29). Diuretics may be used to relieve congestive symptoms.

Treatment of TICMP due to AF involves control of the ventricular response with rate-controlling drugs, use of antiarrhythmic drugs, direct-current cardioversion or catheter ablation of the tachyarrhythmia (Figure 4), in addition to anticoagulation. AF management also aims to reduce symptoms and prevent systemic thromboembolism. Randomized trials comparing outcomes of rhythm versus rate control in AF almost two decades ago found no differences in morbidity or mortality between these approaches. However, patients were included in these trials because the two strategies were considered possible options at baseline, which does not appropriately reflect the clinical setting of patients with TICMP where resolution of the arrhythmia is a main therapeutic target. In addition, ablation was not widely available at that time.

Rate control therapy commonly includes beta-blockers, and/or digitalis. Non-dihydropyridine calcium channel antagonists should be avoided in the context of systolic HF associated with TICMP. Amiodarone can be used in patients otherwise refractory to rate control. Amiodarone is also the most frequently used drug to control the cardiac rhythm in this setting (30). The decision to control the rate or rhythm should be individually tailored (233). Catheter ablation has been used in the setting of AF with HF with the consistent demonstration of an improvement in LVEF, reduction in symptoms and improvement in quality of life. (234-236) Building on these observational series, two recent randomized studies (AATAC and CASTLE-AF) have demonstrated superiority in reducing AF burden, reduced hospitalization and reduced mortality with catheter ablation in systolic heart failure when compared to drug therapy (138, 237). The CAMERA-MRI
study provides further mechanistic insights using cardiac MRI in patients with AF and HF, demonstrating the greatest improvement in LV function in individuals with a lower ventricular fibrosis burden (238). It is important to recognize that these studies enrolled patients with a rather narrow clinical profile and were undertaken in highly specialized units. I.e. they are not fully generalizable to other patient populations.

While these studies included “symptomatic” patients, it is important to recognize that in the setting of HF, it is not always possible to discern the symptoms related to AF from those related to HF. Whether these findings can be extrapolated to the truly “asymptomatic” patient is not known. For now, consideration of ablation as a strategy in the asymptomatic patient will need to be individualized, taking into account patient preference, the experience at each centre and the disease state. Atrial flutter is more difficult to rate control compared to AF. Given the high success rate and low risk of complications with catheter ablation of typical right sided atrial flutter, ablation to eliminate atrial flutter is recommended when TICMP is suspected (31). For atypical atrial flutter this should be decided on an individual basis as indicated before.

A radical form of rate control strategy is atrioventricular (AV) nodal ablation with implantation of a permanent pacemaker programmed to VVIR mode (30). This procedure may be associated with a better prognosis and seems more relevant for older patients with significant co-morbidities (239). Since continuous right ventricular pacing may be deleterious for LV systolic function due to LV dyssynchrony, simultaneous cardiac resynchronization therapy (CRT) as de novo pacing. His bundle pacing holds promise as an attractive mode to achieve more physiological pacing (240).

AV nodal ablation is associated with a substantial reduction in all-cause mortality, cardiovascular mortality and rates of hospitalization for HF, with improvements in New York Heart Association functional class when compared with medical therapy in AF patients receiving CRT in observational and randomized studies (241, 242) and this may apply to patients with AF-related TICMP. AV nodal ablation might be a feasible early strategy in individuals with TICMP and a preexisting pacemaker or CRT device.

PVCs leading to TICMP can either be suppressed by use of antiarrhythmic agents or eliminated by use of radiofrequency ablation (Figure 4) as discussed in section VI. A therapeutic trial with drugs for at least three months or catheter ablation may be considered for patients with presumed PVC-induced TICMP. Beta-blockers, amiodarone and dofetilide (in some countries) can all suppress PVCs and can be safely used in patients with LV dysfunction (243-245). Flecainide is not recommended in this setting. Catheter ablation is a very efficient and recognized option for these patients as the safety and efficacy profiles of the procedure have improved. Several studies have documented an improvement in LVEF following PVC ablation in nearly all patients along with significant reductions in LV end-diastolic dimensions, mitral regurgitation and New York Heart Association functional class (246-248). Short-term ablation success rates of between 70% and 90% have been reported (249, 250). Early improvement in LVEF after ablation may help to predict complete recovery of LV systolic function (250). Although these strategies with antiarrhythmic drugs or ablation differ in their ability to suppress PVCs and in LV dysfunction improvement, their effect has not translated into improvement in survival so far.
There is no data to support safe withdrawal standard heart failure treatment after improvement of left ventricular function.

<table>
<thead>
<tr>
<th>Consensus statements</th>
<th>Symbol</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other cause of cardiomyopathy (myocardial infarction, valve disease, hypertension, alcohol or drug use, stress etc.) should be eliminated before considering a diagnosis of tachycardia induced cardiomyopathy (TICMP)</td>
<td></td>
<td>(195, 223)</td>
</tr>
<tr>
<td>Management of TICMP should involve drug treatment for heart failure, rate control in the case of atrial fibrillation when rhythm control not feasible and rhythm control for the specific arrhythmia (including AF) causing TICMP</td>
<td></td>
<td>(32, 195, 222, 223)</td>
</tr>
<tr>
<td>Ablation may be preferred for rhythm control of persistent or repetitive atrial or ventricular arrhythmia, even when asymptomatic, in suspected TICMP cases.</td>
<td></td>
<td>(32, 223)</td>
</tr>
</tbody>
</table>

**XI. Asymptomatic bradycardia**

Asymptomatic bradyarrhythmias, including sinus node dysfunction (SND) and atrioventricular (AV) conduction disturbances can be noted during routine evaluation or diagnostic workup of an individual who is symptomatic from another cardiac or extracardiac disorder. In this situation it is important to differentiate between those who are truly asymptomatic from individuals who, frequently due to slow progression of the disease, have yet to notice subtle symptoms. For further evaluation, a 24 to 48 hour Holter may give additional information. Also, functional tests such as a treadmill or a stationary bicycle can be useful to evaluate whether there is an appropriate chronotropic response to exercise and to potentially unmask symptoms. A pacemaker is only indicated for symptomatic bradycardia with a very few exceptions.

Very few studies have examined the prognostic value of asymptomatic bradycardia in the general population. From an outpatient database, the long-term outcome of 470 patients > 60 years in age with asymptomatic sinus bradycardia (i.e. heart rate < 55 bpm) was compared with that of 2090 patients without bradycardia (251). During a mean follow-up of 7.2 years, patients with bradycardia had a very low rate of subsequent pacemaker implantation (<1% per year) and asymptomatic bradycardia had no adverse impact on all-cause mortality and may even have been protective. Molgard et al. (252), performed repeated 24-hour Holter monitoring in 183 healthy individuals aged 40-85 years. Pauses were documented in 16-31% of the recordings. Subjects with pauses had a significantly lower average heart rate. Pauses >1.5 sec occurred in 6-6.5% of the subjects whereas pauses ≥2 sec were rare in non-athletes, occurring in 1-1.6% of the subjects. The majority of the pauses were due to SND, mainly sinus arrest in older patients. In another study of 26 elderly (>70 years) subjects studied by Holter monitoring, the longest sinus pauses
were observed during sleep and ranged from 0.8 to 2.5 sec, and were not associated with symptoms (253).

Certain bradyarrhythmias (first degree and second degree Mobitz type I AV block) are common in younger individuals in a resting state and also in competitive athletes. They are generally deemed to be of little concern in the absence of underlying structural heart disease. Recently, a systematic review of the published literature on cardiac pauses in competitive athletes was performed (254). The study population comprised 194 individuals with cardiac pauses of 1.35–3.0 seconds. When specific records for pause durations were provided, 106 athletes had pauses ≤3 seconds, of whom 92 were asymptomatic and 14 had pauses >3 seconds, of whom 9 were asymptomatic. Few subjects were deemed to require medical intervention at the time of diagnosis and there were no deaths during 7.5±5.1 years of follow-up. It was concluded that the accepted 3 second pause threshold does not adequately discriminate between potentially asymptomatic and symptomatic competitive athletes, and in isolation should not be used as a determining factor to exclude potential competitors. Further, the three second pause threshold does not appear to warrant either exercise restriction or early therapeutic intervention.

With the increasing availability of prolonged monitoring techniques, it is not unusual to document even long asymptomatic pauses in patients that have experienced syncope. In the absence of a cause–effect relationship, the meaning of asymptomatic pauses in patients with a diagnosis of unexplained syncope is uncertain. This issue is of practical importance, since a good correlation with the index syncope would allow the use of non-syncopal documented events as surrogate endpoints. Few studies have found a good intra-patient correlation between non-syncopal and syncopal episodes. In a study of 60 patients with unexplained syncope, asymptomatic severe bradyarrhythmias, including > 5 second pauses, > 10 second 3° AV block and heart rate < 30 bpm for > 10 seconds while awake, was observed in 7 patients and led to pacemaker implantation (255).

In a sub-study of the ISSUE2 study, Moya et al. (256), correlated the ECG findings saved by an implantable loop recorder (ILR) during non-syncopal episodes, either pre-syncope or nonspecific symptoms, with those recorded during syncope in order to evaluate their possible role in predicting the mechanism of syncope. Nine patients had an automatic activation of their ILR, i.e. were asymptomatic, and 9 had nonspecific symptoms. In these 18 patients, the documentation of an arrhythmia showed a high probability as a diagnostic finding, making it unnecessary to wait for syncope to be documented and allowing, in those cases in which it is considered indicated, to initiate therapy earlier.

There are limited data regarding the beneficial effect of pacing in patients with a history of syncope but with asymptomatic intermittent bradycardia without extended pauses during monitoring. The length of the documented pause is of importance for the decision to implant a pacemaker. While ventricular pauses of 3 seconds or longer are uncommon, these pauses usually do not cause symptoms, and the presence of these pauses does not necessarily portend a poor prognosis or the need for pacing in asymptomatic patients (257). The position of the patients when the pause occurs may have an impact on how long a pause is needed to impact
consciousness. In patients with a clinical diagnosis of neurocardiogenic syncope and asymptomatic pause(s) >6 seconds, there is weak evidence that cardiac pacing may be effective and useful for the reduction of syncopal recurrences. The rationale behind the 6 second cut-off value includes data showing that loss of consciousness may take up to 7 seconds in case of circulatory arrest (11).

In patients presenting with asymptomatic intermittent night time bradycardia (sinus bradycardia or AV block), sleep apnea should be considered as a possible cause. It was estimated that episodes of heart block occur in approximately 20% of patients with severe sleep apnea, i.e. apnea–hypopnea index >60/h and approximately 7.5% of an unselected group of patients with obstructive sleep apnea (258). Rapid eye movement sleep and excessive vagal activation due to hypoxia and apnea seem to be important mechanisms leading to bradycardia. Treatment with continuous positive airway pressure should be attempted first, since it has been shown to lead to a complete prevention of heart block in 80–90% of these patients.

It is not uncommon to record asymptomatic episodes of AV block on prolonged ECG monitoring. Asymptomatic bradycardia is not uncommon and interpretation of this should be made in the clinical context of the patient. In healthy subjects pauses >2.5 seconds are infrequent but this alone does not necessarily define a clinical disorder. Asymptomatic bradycardia is common in athletes and the accepted 3 second pause threshold neither warrants exercise restriction or early therapeutic intervention (254). Pauses in AF patients between 3 to 5 seconds are frequently seen and may be a normal occurrence. Treatment is not required except in case of symptoms.

In the case of AV block, it is crucial to distinguish nodal from infra-nodal localizations, the latter usually requiring pacemaker implantation. Key for this distinction are the type of AV block, the presence or absence of wide QRS complexes and the heart rate changes at the time of AV block. Progressive PR prolongation prior to the nonconducted P wave is typical for type I second degree AV block. True type II second degree AV block should be recognized through careful analyses of the tracings since it denotes a severe disease of the conduction system and may in most cases warrant pacemaker implantation. In the case of a single asymptomatic nonconducted P wave a decision should be made on a case by case basis. When wide QRS complexes are present, an infra-Hisian localization should be considered, even in case of type I second degree AV block and may prompt an electrophysiological study. Slowing of the heart rate at the time of AV block is diagnostic of AV nodal localization while block in the His-Purkinje system can be tachycardia-dependent. In addition, careful analysis of the tracings should rule out concealed His bundle extrasystoles which may mimic both types I and/or II AV block. Exercise testing may be beneficial to identify infra-Hisian block. There is some data indicating that pacing of type 1 second-degree AV block may be of benefit in selected asymptomatic elderly individuals (259). However, this area clearly needs further investigation before any conclusive recommendations can be made.

There is a consensus that third degree AV block in the absence of correctable causes and Type II second degree AV block (Mobitz II) should be treated with a pacemaker even in the absence of symptoms given the potential severity of these findings (260).
<table>
<thead>
<tr>
<th>Consensus statements</th>
<th>Symbol</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>In individuals with syncope the presence of asymptomatic severe bradycardia or pauses &gt;6 seconds should be considered a diagnostic finding and lead to treatment.</td>
<td>![Yellow Heart]</td>
<td>(261)</td>
</tr>
<tr>
<td>Completely asymptomatic bradycardia does in itself not require treatment.</td>
<td>![Red Heart]</td>
<td>(260, 262)</td>
</tr>
</tbody>
</table>

**XII. Patient perspective**

As clearly stated in the document, cardiac arrhythmias can be episodic or persistent, and in many individuals they may be asymptomatic. However, the absence of symptoms in arrhythmic conditions does not necessarily mean that the patient does not require treatment or is not at risk of adverse outcomes. Indeed, asymptomatic cardiac arrhythmias may be associated with worse outcomes as often the detection of the arrhythmia is made following a first presentation to hospital for a serious arrhythmia-related event, such as stroke (in AF), cardiac arrest (e.g., ventricular arrhythmias), or TICMP.

Even in the absence of symptoms, once an arrhythmia has been diagnosed, patients may still experience significant distress and worries about the arrhythmia. This may extend to the therapeutic options with their possible side-effects (e.g., bleeding with oral anticoagulant therapy, side effects of AADs and other medications, ICD implantation etc.) and the potential consequences of the arrhythmia (death, stroke, heart failure, etc.) (263-266). Absence of symptoms may also affect the choices that the individual makes in regard to treatment pathway/options, as the patient may perceive that they have ‘less severe’ disease due to lack of symptoms. This may in turn lessen their appreciation of the seriousness of the consequences of the arrhythmia and the necessity of treatment. Lack of symptoms may also affect the treatment options offered to patients, for example in AF rhythm-control strategies (cardioversion and ablation) are usually targeted at symptomatic patients, as the goal of such therapy is symptom reduction or resolution. Lifestyle restrictions and/or modifications frequently accompany a cardiac arrhythmia diagnosis, either directly as result of the arrhythmia (e.g., inherited arrhythmia disorders, WPW, etc.) or of the treatment options required to manage the arrhythmia (e.g., ICD). In those with an inherited arrhythmia or WPW, the diagnosis typically occurs when the patient is relatively young and otherwise fit and well and such a diagnosis may permanently alter the quality of life and may lead to profound psychological distress (264, 267).

It is essential that, regardless of the type of arrhythmia, patients are fully informed about the trajectory of their condition; the available treatment options (risks and benefits and side effects, particularly for ICD implantation); lifestyle changes that are required to modify their risk factors and reduce their risk of adverse outcomes; likelihood of treatment success and what can be
achieved so that people can form realistic expectations of treatment and make informed
decisions about the treatment options that are right for them (48, 66, 144, 268, 269). Patient
education is a fundamental part of arrhythmia management (66, 268, 270), irrespective of
symptoms. It is also crucial to acknowledge patients’ concerns and assess and monitor the
psychological impact of the arrhythmia and its treatment on the patient and their family, and to
formulate a plan to manage distress (66), since psychological distress can influence patient
adherence and persistence with treatment and drastically reduces patients’ quality of life and
that of their families (271-276), irrespective of the presence or absence of symptoms.

A 2015 EHRA consensus document summarizes the current literature on cardiac arrhythmias and
patients values and preferences for their management (66) and also provides important topics
for physician-patient discussions concerning their arrhythmia and disease course, treatment
options and goals, and outcomes, and helpful resources to elicit these conversations.

Shared decision-making should be the approach adopted to accomplish this target; incorporating
both the patient and the physician/healthcare professional, mutual shared information, bilateral
(patient and physician) deliberation about preferences, options, and reaching a shared treatment
decision (including no treatment as a possibility).

<table>
<thead>
<tr>
<th>Consensus statements</th>
<th>Symbol</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Education is an essential component of the management of cardiac arrhythmias to enable patients (and their carers/family members) to understand their condition, the available treatments, disease trajectory, and possible outcomes, regardless of symptoms.</td>
<td><img src="heart.png" alt="Heart" /></td>
<td>(66)</td>
</tr>
<tr>
<td>All patients should receive individually tailored disease- and treatment-specific information from their healthcare team which is reiterated over time and when new management strategies are discussed.</td>
<td><img src="heart.png" alt="Heart" /></td>
<td>(66)</td>
</tr>
<tr>
<td>Patients’ preferences for treatment should be discussed, documented, and incorporated into management decisions.</td>
<td><img src="heart.png" alt="Heart" /></td>
<td>(66)</td>
</tr>
</tbody>
</table>

XIII. Areas of future concern

During the process of writing this consensus document on asymptomatic arrhythmias it became increasingly evident that there is a significant paucity of data from studies that are adequately
represented by asymptomatic patients. Many of the sections in this consensus document have included data which have been extrapolated from studies on predominantly symptomatic arrhythmias and some even from highly selected subgroups. Therefore the formation of recommendations for asymptomatic arrhythmias has in some cases been a somewhat complex task. Also, asymptomatic arrhythmias vary considerably regarding their risk to cause adverse effects and the need to intervene. Nevertheless, in instances where no treatment might lead to potentially severe consequences, such as stroke in AF and subsequent cardiac arrest in individuals with sustained VT, it would irresponsible to withhold treatment despite lack of symptoms from the arrhythmia.

The reasons for the lack of symptoms in some individuals are still poorly understood. While treatments aiming to decrease the perception of benign symptomatic arrhythmias are common, technology aiming to enhance patients and care providers awareness of serious arrhythmias could also be useful. Such alerts as an example already exist in some CIEDs and serve the purpose to notify a patient having an asymptomatic but potentially malignant ventricular arrhythmia.

The consumerization of medical devices will likely lead to a significant increase the diagnostic yield and observed prevalence of asymptomatic tachycardia, bradycardia, and probably atrial fibrillation in the very near future. A number of companies including Fitbit, Garmin, Apple, and Samsung, all have devices on the market with heart rate alert features. Smartwatch and fitness band wearable consumer electronics can passively measure pulse rate from the wrist using photoplethysmography. Identification of pulse irregularity or variability from these data has the potential to identify AF. The rapidly expanding consumer base of these devices will allow for detection of undiagnosed AF in a completely new manner. Other companies, including AliveCor and Withings also have ECG watches or watch accessories. Apple has an irregular rhythm notification now that is being prospectively evaluated in a clinical trial which will include more than 400,000 individuals (277). While the opportunities created by these possibilities are exciting, they will undoubtedly emphasize the need for clearer guidance on how and when to intervene in those with asymptomatic heart rhythm abnormalities.

Although this document focuses mostly on asymptomatic arrhythmias, patients should be warned of symptoms they might develop or have been dismissed in the past. In particular the features of syncope and near syncope. Important medical mis-assessments have included diagnosis of anxiety and/or hypoglycemia in patients that have arrhythmias.

Finally, in many different asymptomatic heart rhythm irregularities, the distinction between significant and non significant burden of the arrhythmia remains unclear. Furthermore, some arrhythmias could have been diagnosed during either direct or indirect screening, or because of the increased use of detection devices, such as smartphones apps, or special watches. These individuals may represent a group having an even lower burden of arrhythmias, and to the same extent as subclinical AF discovered through CIEDs, using continuous monitoring, may represent potentially less harmful arrhythmias. Further studies are needed to evaluate the seriousness and net clinical benefit of treatment in these patients.
References


working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2018;20(1):e1-e160.


Table 1 Scientific rationale behind colored hearts recommendations

<table>
<thead>
<tr>
<th>Definitions where related to a treatment or procedure</th>
<th>Consensus statement instruction</th>
<th>Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific evidence that a treatment or procedure is beneficial and effective. Requires at least one randomized trial, or is supported by strong observational evidence and authors’ consensus (as indicated by an asterisk).</td>
<td>‘Should do this’</td>
<td>🍀</td>
</tr>
<tr>
<td>General agreement and/or scientific evidence favour the usefulness / efficacy of a treatment or procedure. May be supported by randomized trials based on a small number of patients or which is not widely applicable.</td>
<td>‘May do this’</td>
<td>🍋</td>
</tr>
<tr>
<td>Scientific evidence or general agreement not to use or recommend a treatment or procedure.</td>
<td>‘Do not do this’</td>
<td>🍃</td>
</tr>
</tbody>
</table>
Table 2. Detection of asymptomatic AF: Clinical setting, screening methods and screening tools.

<table>
<thead>
<tr>
<th>Clinical setting</th>
<th>Screening methods</th>
<th>Screening tools</th>
</tr>
</thead>
</table>
| Clinically detected | • Pulse check  
• Opportunistic screening  
• Screening of a pre-defined population at increased risk of AF (e.g., the elderly, post-stroke patients)  
• Community screening of all subjects living in a specific area  
• Systematic screening of the population | • Clinical (patient history, risk scores, pulse checking, BP measurement)  
• Single-lead ECG (electrical stick, monitor, monitoring patch, watch-like recorder)  
• Multi-lead ECG (Holter monitoring, Multielectrode belt)  
• Loop recoder |
| Preparatory settings | • Pulse check  
• Opportunistic screening  
• Screening of a pre-defined population at increased risk of AF (e.g., the elderly, post-stroke patients)  
• Community screening of all subjects living in a specific area  
• Systematic screening of the population | • Clinical (patient history, risk scores, pulse checking, BP measurement)  
• Single-lead ECG (electrical stick, monitor, monitoring patch, watch-like recorder)  
• Multi-lead ECG (Holter monitoring, Multielectrode belt)  
• Loop recoder |
| Preparation for surgery or an invasive intervention  
Self-detected by home BP measurement or pulse checking | |

Detection of subclinical AF and AHREs

<table>
<thead>
<tr>
<th>Clinical setting</th>
<th>Screening methods</th>
<th>Screening tools</th>
</tr>
</thead>
</table>
| Patients implanted with a CIED (e.g., anti-bradycardia PM, ICD) for other reasons  
Patients implanted with a cardiac monitoring device due to symptoms suggestive of an arrhythmia, post syncope, etc. | • Opportunistic screening in patients implanted with a CIED for other reasons  
Targeted screening for AF in patients at increased risk of AF (e.g., post an embolic stroke - ESUS) | |
| | |

AF: Atrial Fibrillation; BP: Blood pressure; ECG: Electrocardiography; AHRE: Atrial High Rate Episodes; CIED: Cardiac Implantable Electronic Device); PM: Pacemaker; ICD: Implantable Cardioverter Defibrillator; ESUS: Embolic Stroke of Undetermined Etiology; ICM: Implantable Cardiac Monitor.

Asymptomatic AF refers to AF diagnosed by conventional means while subclinical AF is used to denote AF diagnosed by implantable devises only.
Table 3. Baseline characteristics and outcomes in asymptomatic AF patients: post-hoc analyses of RCTs and observational studies.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Study type</td>
<td>RCT, post-hoc</td>
<td>RCT, post-hoc</td>
<td>Retrospective</td>
<td>Single-centre, first-onset AF</td>
<td>Administrative dataset</td>
<td>International registry</td>
<td>International registry</td>
<td>Retrospective</td>
<td>Community-based survey</td>
</tr>
<tr>
<td>Cohort size (n)</td>
<td>4060</td>
<td>522</td>
<td>4,618</td>
<td>1,100</td>
<td>30,260</td>
<td>3,119</td>
<td>10,087</td>
<td>476</td>
<td>3,749</td>
</tr>
<tr>
<td>Asymptomatic AF</td>
<td>12%</td>
<td>30%</td>
<td>25%</td>
<td>13.3%</td>
<td>18.4%*</td>
<td>39.7%</td>
<td>38.2%</td>
<td>33.8%</td>
<td>52.6%</td>
</tr>
<tr>
<td>Follow-up (mean)</td>
<td>3.5 y</td>
<td>2.3±0.6 y</td>
<td>9.9±6.1 years</td>
<td>≤3 years</td>
<td>1 year</td>
<td>Median 1.8 y</td>
<td>Median 6.0 y</td>
<td>3.0 y</td>
<td></td>
</tr>
</tbody>
</table>

Baseline characteristics of patients with asymptomatic AF

- Male predominance
- Older age
- Non-paroxysmal AF
- Slower heart rate
- More comorbidity
- Higher stroke risk

Treatment differences

- Rate control
- Rhythm control
- OAC

Outcomes (asymptomatic AF vs comparator**)
<table>
<thead>
<tr>
<th>AF progression</th>
<th>1.6 (1.1-2.2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6% vs 7%</td>
</tr>
<tr>
<td></td>
<td>1.07 (0.79-1.46)</td>
</tr>
<tr>
<td>Mortality</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.7 (0.4-1.1)</td>
</tr>
<tr>
<td>MI</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0% vs 6%</td>
</tr>
<tr>
<td>Heart failure</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Dementia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Major bleeding</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4% vs 4%</td>
</tr>
</tbody>
</table>

More common in asymptomatic AF; No difference; Less common in asymptomatic AF; Greater risk of worse prognosis; Not reported.

*Patients incidentally diagnosed with AF were compared to matched non-AF controls; otherwise, the comparator was symptomatic AF. *Outcomes presented as crude incidence rates per 1000 patient-years; otherwise, Hazard Ratios (95% Confidence Interval) or event rate, where reported. RCT: Randomized Clinical Trial; AFFIRM: Atrial Fibrillation Follow-up Investigation of Rhythm Management; RACE: Rate Control versus Electrical cardioversion for persistent atrial fibrillation.
Table 4: Factors that may point to worse prognosis in patients with PVCs and that need a thorough investigation to rule out underlying structural, ischemic or electrical disease. The additional evaluations should be individually tailored, in analogy with the flowchart in Figure 3.

- Underlying structural, ischemic or electrical disease
- More than 2000 PVC / 24 hours
- Complex PVCs (couplets, triplets, non-sustained VT)
- Increasing number of morphologies
- Increasing number PVCs with exercise
- Non-outflow tract PVC (usually monomorphic or only slightly divergent morphologies)
- Short coupling interval of the PVCs (“R-on-T”)
- PVCs with broader QRS complexes (more frequently related to cardiomyopathy)
Table 5: Summary of studies relating PVC burden with LV dysfunction

<table>
<thead>
<tr>
<th>Study</th>
<th>No of patients with PVCs</th>
<th>No of patients (asymptomatic)</th>
<th>No of patients with LV dysfunction (definition)</th>
<th>PVC burden (no LV dysfunction)</th>
<th>PVC burden (LV dysfunction)</th>
<th>PVC burden predictive for LV dysfunction</th>
<th>Lowest PVC burden with LV dysfunction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baman et al. (231) (2010)</td>
<td>174</td>
<td>17</td>
<td>57 (LVEF&lt;50%)</td>
<td>13+/-12%</td>
<td>33+/-13%</td>
<td>24% (sensitivity 79%, specificity 78%)</td>
<td>10%</td>
</tr>
<tr>
<td>Hasdemir et al. (177) (2011)</td>
<td>249</td>
<td>26</td>
<td>17 (LVEF&lt;50%)</td>
<td>8.1+/-7.4</td>
<td>29+/-9.2%</td>
<td>16% (sensitivity 100%, specificity 87%)</td>
<td>_</td>
</tr>
<tr>
<td>Munoz et al. (173) (2011)</td>
<td>70</td>
<td>-</td>
<td>17 (LVEF&lt;50%)</td>
<td>16.7+/-13.7</td>
<td>29.3+/-14.6%</td>
<td>15/17 had PVC burden &gt;10%</td>
<td>2/17 had PVC burden &lt;10%</td>
</tr>
<tr>
<td>Ban et al. (230) (2013)</td>
<td>127</td>
<td>7</td>
<td>28 (LVEF&lt;50%)</td>
<td>22+/10%</td>
<td>31+/-11%</td>
<td>26% (sensitivity 70%, specificity 78%)</td>
<td>_</td>
</tr>
<tr>
<td>Blaye-Felice et al. (172) (2016)</td>
<td>186</td>
<td>-</td>
<td>96 (LVEF&lt;50%)</td>
<td>17+/-12%</td>
<td>26+/-12%</td>
<td>_</td>
<td>10/96 had PVC burden &lt;10%</td>
</tr>
<tr>
<td>Lie et al. (278) (2017)</td>
<td>52</td>
<td>-</td>
<td>15 (GLS worse than -18%)</td>
<td>5%</td>
<td>22%</td>
<td>&gt;8%</td>
<td>_</td>
</tr>
<tr>
<td>Park et al. (279) (2017)</td>
<td>180</td>
<td>36</td>
<td>52 (LVEF &lt;50%)</td>
<td>28+/-11.6%</td>
<td>30.7+/-10%</td>
<td>26% (sensitivity 63%, specificity 87%)</td>
<td>_</td>
</tr>
</tbody>
</table>
### Table 6. Definitions of different sub-types of ventricular tachycardia

<table>
<thead>
<tr>
<th>Type of ventricular arrhythmia</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-sustained VT</td>
<td>Three or more consecutive ventricular beats terminating spontaneously in less than 30 seconds with a cycle length of &lt;600 ms (&gt;100 bpm)</td>
</tr>
<tr>
<td>-Non-sustained monomorphic VT</td>
<td>NSVT with a single QRS morphology</td>
</tr>
<tr>
<td>-Non-sustained polymorphic VT</td>
<td>NSVT with a changing QRS morphology and a cycle length between 600 and 180 ms</td>
</tr>
<tr>
<td>Monomorphic sustained VT</td>
<td>VT greater than 30 seconds in duration or terminated by external intervention with a stable QRS morphology</td>
</tr>
<tr>
<td>Bidirectional VT</td>
<td>VT with a beat to beat alternans in the frontal plane axis often associated with digitalis toxicity or channelopathies such as CPVT or Andersen-Tawil syndrome</td>
</tr>
</tbody>
</table>
| Torsades de pointes                    | Polymorphic VT characterized by twisting of the peaks of the QRS complexes around the isoelectric line often associated with long QT.  
- Typical: initiation following a long/short/long coupling interval  
- Atypical: short coupled variant initiated by R on T PVCs                                           |
| Accelerated idioventricular rhythm     | Ventricular rhythm slower than <100 bpm                                                                                                                                                                   |

*Ms: milliseconds; NSVT: non-sustained ventricular tachycardia; VT: ventricular tachycardia*
Table 7. Evaluation of patients with asymptomatic sustained or non-sustained VT

<table>
<thead>
<tr>
<th>First line evaluation</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>History</strong></td>
<td>Prior cardiovascular disease, Hypertension, Syncope or near-</td>
</tr>
<tr>
<td></td>
<td>syncope, Relation of VT to exercise...</td>
</tr>
<tr>
<td><strong>Family history</strong></td>
<td>SCD, inherited arrhythmia syndromes, coronary artery disease,</td>
</tr>
<tr>
<td></td>
<td>cardiomyopathy?</td>
</tr>
<tr>
<td><strong>Medications</strong></td>
<td>QT prolonging drugs, sodium channel blockers, drug interactions?</td>
</tr>
<tr>
<td><strong>Physical examination</strong></td>
<td>Sign of structural heart disease or heart failure</td>
</tr>
<tr>
<td>** Twelve-lead ECG**</td>
<td>Q-waves, ischaemic changes, prolonged or fractionated QRS, QT</td>
</tr>
<tr>
<td></td>
<td>prolongation or shortening, J point elevation and coved-type ST</td>
</tr>
<tr>
<td></td>
<td>elevation V1–V3, early repolarization, epsilon waves, or T-wave</td>
</tr>
<tr>
<td></td>
<td>inversion anteriorly, laterally or inferiorly</td>
</tr>
<tr>
<td><strong>Prolonged rhythm monitoring</strong></td>
<td>Day/night/effort appearance</td>
</tr>
<tr>
<td></td>
<td>Frequency and duration of episodes</td>
</tr>
<tr>
<td><strong>Echocardiography</strong></td>
<td>Sign of structural heart disease</td>
</tr>
<tr>
<td><strong>Laboratory</strong></td>
<td>Serum electrolytes, renal function, thyroid function and BNP</td>
</tr>
<tr>
<td><strong>Stress test</strong></td>
<td>Suspicion of coronary artery disease, exercise-related symptoms,</td>
</tr>
<tr>
<td></td>
<td>borderline QT interval. VT provocation by exertion</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Second line evaluation</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-invasive evaluation of</strong></td>
<td>Low suspicion of coronary artery disease</td>
</tr>
<tr>
<td><strong>coronary artery</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Coronary arteriography</strong></td>
<td>High suspicion of coronary artery disease</td>
</tr>
<tr>
<td><strong>Cardiac MRI</strong></td>
<td>Suspicion of structural heart disease such as ARVC, HCM, cardiac</td>
</tr>
<tr>
<td></td>
<td>sarcoidosis, congenital abnormalities</td>
</tr>
<tr>
<td><strong>Electrophysiological study</strong></td>
<td>In case of NSVT, coronary artery disease and moderate LV</td>
</tr>
<tr>
<td></td>
<td>dysfunction (EF&lt;40%), syncope</td>
</tr>
<tr>
<td><strong>Pharmacological testing</strong></td>
<td>To unmask suspected Brugada syndrome</td>
</tr>
<tr>
<td>- Ajmaline test</td>
<td></td>
</tr>
<tr>
<td>- Flecaainide test</td>
<td></td>
</tr>
<tr>
<td><strong>Genetic Testing</strong></td>
<td>In case of suspicion of inherited arrhythmic disorders</td>
</tr>
</tbody>
</table>

ARVC: arrhythmogenic right ventricular cardiomyopathy; HCM: hypertrophic cardiomyopathy; LV: left ventricular; NSVT: non-sustained ventricular tachycardia; SCD: sudden cardiac death; VT: ventricular tachycardia
Table 8. Treatment of asymptomatic patients with NSVT depending on underlying structural heart disease

<table>
<thead>
<tr>
<th>Clinical Setting</th>
<th>Risk of sudden cardiac death</th>
<th>Prognostic evaluation</th>
<th>Treatment</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute STEMI&lt;48 hours</td>
<td>Not increased</td>
<td>Coronary artery disease</td>
<td>- Optimal medical therapy including beta-blocker - Revascularization</td>
<td>(280, 281)</td>
</tr>
<tr>
<td>Acute STEMI &gt;48 hours</td>
<td>Increased risk</td>
<td>Waiting for 6 weeks post MI</td>
<td>- Optimal medical therapy (ACE inhibitors, beta-blockers and mineralocorticoid receptor antagonist)</td>
<td>(280, 281)</td>
</tr>
<tr>
<td>Previous MI, LVEF 36-40%</td>
<td>Increased risk</td>
<td>PVS</td>
<td>ACEI, beta-blocker +/- ICD depending on PVS</td>
<td>(282, 283)</td>
</tr>
<tr>
<td>Previous MI, LVEF≤35%</td>
<td>Increased risk</td>
<td>Careful evaluation of LVEF</td>
<td>ACE, beta-blocker, mineralocorticoid receptor antagonist ICD</td>
<td>(283, 284)</td>
</tr>
<tr>
<td>Non-ischemic dilated CMP</td>
<td>Uncertain</td>
<td>Uncertain - Cardiac MRI to identify an underlying substrate - PVS is controversial</td>
<td>- Optimal medical therapy (ACE inhibitors, Beta-blockers and mineralocorticoid receptor antagonist) - ICD if LVEF&lt;30% See relevant guidelines</td>
<td>(7, 201, 285, 286)</td>
</tr>
<tr>
<td>Myocarditis sequelae</td>
<td>Uncertain</td>
<td>Uncertain - Cardiac MRI to identify an underlying substrate</td>
<td>- Beta-blockers - ICD when LVEF&lt;30% and acute phase of myocarditis ruled out</td>
<td>(7)</td>
</tr>
<tr>
<td>Condition</td>
<td>Possible increase in risk</td>
<td>NSVT defined as ≥3 consecutive ventricular beats at ≥120 BPM lasting &lt;30 seconds</td>
<td>Determinate other criteria for risk stratification: TTE, Cardiac MRI, Stress test or stress echo, genetic testing</td>
<td>Benefits of beta-blocker unclear - ICD may be discussed in selected cases</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Mitral valve prolapse CMP</td>
<td>Possible increased risk</td>
<td>Uncertain -Cardiac MRI to identify myocardial scar</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCM</td>
<td>Increased risk</td>
<td>Determine other criteria for risk stratification: TTE, Cardiac MRI, Stress test or stress echo, genetic testing</td>
<td>ICD or nothing depending on risk stratification (see relevant guidelines)</td>
<td></td>
</tr>
<tr>
<td>ARVC</td>
<td>Probably increased risk</td>
<td>- Evaluation of RV and LV function - Consider PVS</td>
<td>- Beta-blocker - ICD should be discussed according to risk stratification - Consider catheter ablation in carefully selected cases</td>
<td></td>
</tr>
<tr>
<td>Left ventricular non-compaction</td>
<td>Uncertain</td>
<td>None</td>
<td>Same criteria than for non-ischemic dilated CMP</td>
<td></td>
</tr>
<tr>
<td>Cardiac Amyloidosis</td>
<td>Uncertain</td>
<td>None</td>
<td>-Specific treatment of amyloidosis -No ICD indication for primary prevention at present time</td>
<td></td>
</tr>
</tbody>
</table>

Table 9: Treatment of patients with asymptomatic ventricular arrhythmias in the setting of channelopathies

<table>
<thead>
<tr>
<th>Asymptomatic ventricular arrhythmia</th>
<th>Treatment options</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monomorphic sustained or non-sustained VT</td>
<td>If evaluation for structural heart disease with echo, cardiac MRI is normal, no therapy. Need follow up and monitoring of LV function</td>
</tr>
<tr>
<td>Polymorphic VT</td>
<td>Culprit PVC ablation</td>
</tr>
<tr>
<td></td>
<td>Discuss ICD and/or quinidine</td>
</tr>
<tr>
<td>MEPPC</td>
<td>Discuss quinidine</td>
</tr>
<tr>
<td>Andersen Tawil</td>
<td>Beta-blockers</td>
</tr>
<tr>
<td></td>
<td>+/- flecainide or calcium channel blocker</td>
</tr>
<tr>
<td>CPVT on beta-blockers</td>
<td>Ascertain the intake of beta-blocker</td>
</tr>
<tr>
<td></td>
<td>Add flecainide and/or left cardiac sympathetic denervation</td>
</tr>
<tr>
<td></td>
<td>Discuss ICD</td>
</tr>
<tr>
<td>Long QT syndrome</td>
<td>Correction of hypokalemia if present</td>
</tr>
<tr>
<td></td>
<td>Careful consideration of QT prolonging drug withdrawal. Consider genetic testing and beta-blockers if no reversible cause found</td>
</tr>
<tr>
<td>Brugada syndrome and early repolarization syndrome</td>
<td>Quinidine</td>
</tr>
<tr>
<td></td>
<td>Discuss ICD with expert in Brugada syndrome</td>
</tr>
</tbody>
</table>

CPVT: catecholaminergic polymorphic ventricular tachycardia, ICD: Implantable cardioverter defibrillator, MEPPC: multifocal ectopic Purkinje-related premature contractions, PVC: premature ventricular contractions, VT: ventricular tachycardia
**Table 10.** Types of arrhythmias that can lead to tachycardia-mediated cardiomyopathy.

<table>
<thead>
<tr>
<th><strong>Supraventricular tachycardia</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Atrial fibrillation</td>
<td></td>
</tr>
<tr>
<td>• Atrial flutter</td>
<td></td>
</tr>
<tr>
<td>• Atrial tachycardia</td>
<td></td>
</tr>
<tr>
<td>• Permanent junctional reciprocating tachycardia</td>
<td></td>
</tr>
<tr>
<td>• AV nodal re-entrant tachycardia</td>
<td></td>
</tr>
<tr>
<td>• AV re-entrant tachycardia</td>
<td></td>
</tr>
<tr>
<td>• Inappropriate sinus tachycardia (rare)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Ventricular tachycardia</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Any type of ventricular tachycardia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Premature contractions</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• High burden of premature ventricular contractions</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Pacing</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• High-rate atrial pacing</td>
<td></td>
</tr>
<tr>
<td>• Persistent rapid ventricular pacing</td>
<td></td>
</tr>
<tr>
<td>• Permanent pacing with right ventricular stimulation</td>
<td></td>
</tr>
</tbody>
</table>
Table 11. Possible pathophysiological mechanisms leading to tachycardia induced cardiomyopathy

- Alteration in systolic function: left ventricular dilation with lack of hypertrophy
- Alteration in diastolic function: incomplete relaxation (diastolic contracture)
- Alteration in diastolic function: decreased filling time
- Loss of atrial contraction for atrial arrhythmias
- Atrial contractile dysfunction in sinus rhythm for atrial arrhythmias with atrial cardiomyopathy
- Cardiac desynchronization at the atrioventricular level for ventricular arrhythmias
- Cardiac desynchronization at the interventricular level for ventricular arrhythmias or atrial arrhythmias with functional bundle branch block.
- Depletion of myocardial phosphates energy stores
- Decreased myocardial blood flow
- Oxidative stress
- Decreased response to beta-adrenergic stimulation
- Activation of the renin–angiotensin–aldosterone
- Mitral regurgitation developing with dilated cardiomyopathy
- Changes in right ventricular myocardial geometry (hypertrophy)
- Left ventricular hypertrophic response during recovery from TICMP
Table 12. Elements for the diagnosis of tachycardia induced cardiomyopathy

1. No other cause of cardiomyopathy (myocardial infarction, valve disease, hypertension, alcohol or drug use, stress etc.)
2. Absence of left ventricular hypertrophy
3. No major increase in LV dimensions (LV end-diastolic dimension <6.5 cm)
4. Recovery of LV function after control of tachycardia (by rate control, cardioversion or radiofrequency ablation) within a time frame of one to six months.
5. Rapid decline in LVEF following recurrence of tachycardia in a patient with recovered LV function after previous control of tachycardia.
Table 13. Possible predictors or elements associated with development of TICMP

**TICMP induced by supraventricular tachycardia**

- Younger age
- Male sex
- Slower tachycardia (with less symptoms before heart failure is present)
- Incessant arrhythmia
- Irregularity of R-R interval
- Lack of symptoms in AF of atrial flutter

**TCIMP induced by premature ventricular contractions (PVC)**

- PVC burden (from >10,000/24h to >24% of total beats; threshold may be lower for right as compared to left ventricular PVCs)
- Wider PVCs
- PVCs of epicardial origin
- Presence of interpolated PVCs
- Presence of retrograde P waves
- PVCs that are asymptomatic
Figure 1: The Atrial fibrillation Better Care (ABC) pathway depicting some key components of AF management.

- **Asymptomatic AF**
  - Atrial and ventricular remodeling
  - More advanced remodeling at the time of AF diagnosis, due to longer duration of undetected AF

- **Detect and manage AF**
  - The Atrial fibrillation Better Care (ABC) pathway
  - **Avoiding stroke (optimize stroke prevention, consider OAC use)**
  - **Better symptom management (rate or rhythm control)**
  - **Cardiovascular and non-cardiovascular risk factors/conditions management**

- **AF-related outcomes**
  - Heart failure (incident/worsening)
  - Stroke/Systemic embolism
  - Renal dysfunction (incident/worsening)
  - Cognitive impairment/Dementia
  - Hospitalization
  - Mortality
  - Impaired quality of life

- **IMPROVE THE OUTCOMES**
  - Manage hypertension, heart failure, diabetes mellitus, cardiac ischemia, sleep apnoea
  - Lifestyle changes (weight control, reduction of alcohol and stimulant use)
  - Consider patient values and preferences

- **“Birmingham 3-step approach”**
  1. Identify low-risk patients
  2. Offer stroke prevention to patients with $\geq 1$ stroke risk factors; Assess bleeding risk
  3. Choose OAC* (a VKA with well-managed TTR or a NOAC)

Search for atypical symptoms, determine if truly asymptomatic patient
- In-dept history
- A trial of rhythm control (e.g., DC cardioversion)
- Manage symptoms in patients with confirmed atypical symptoms

Quantify AF burden
- Consider AF ablation** in selected asymptomatic patients (younger patients, with paroxysmal or persistent AF)
**Figures 2a-b.** Annual stroke rates (y-axis) among non-anticoagulated patients with paroxysmal, persistent and permanent AF (x-axis) and ≥1 CHA$_2$DS$_2$-VASc stroke risk factor.

![Graph showing annual stroke rates among non-anticoagulated patients with different types of AF and CHA$_2$DS$_2$-VASc risk factor](image-url)
Figure 2b
Figure 2c. Major bleeding rates (y-axis) among anticoagulated AF patients were broadly similar across AF types (x-axis)
Figure 3.
Evaluation of patients with > 500 premature ventricular contractions per 24 hours. There is no defined set of “minimal investigations”, but conceptually three axes of evaluation need to be explored (imaging, electrical and genetic) and investigations considered on an a case to case basis.
Figure 4. Potential management strategy for patients with tachycardia induced cardiomyopathy (TICMP)

- **Rate control for those with AF**
  - Beta blocker or calcium channel antagonist + digoxin
  - AV nodal ablation and permanent pacemaker
  (consider CRT of His pacing if de novo pacing) when insufficient rate control with drugs or rhythm control failed or deemed unsuitable

- **Rhythm control for the specific arrhythmia suspected of causing TICMP**
  - Cardioversion in case of AF
  - Antiarrhythmic therapy with amiodarone
  - Consider ablation for persistent arrhythmia
## Supplemental table.

### Studies on PACs and their association with AF and stroke (for supplement)

<table>
<thead>
<tr>
<th>Study</th>
<th>Study population</th>
<th>Cardiac Monitoring</th>
<th>Design (primary endpoint)</th>
<th>N (% Females; follow-up time)</th>
<th>Age</th>
<th>ESVEA Definition</th>
<th>Main finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bicini et al. (2010)</td>
<td>Normal middle aged persons without known cardiovascular disease</td>
<td>48-h Holter on inclusion</td>
<td>Prospective (association between ESVEA and strokes or death)</td>
<td>678 subjects (41.4%; 6.3 years)</td>
<td>Median age 64.5 (SD 6.8)</td>
<td>ESVEA: More than 30 APCs per hour or any 20 APCs in run</td>
<td>ESVEA associated with: Stroke/death: HR 1.64 (CI 1.03-2.60; p&lt;0.036) Admission for AF: HR 2.78 (1.08-6.99; p&lt;0.033) Also as a continuous variable SVEC was associated with stroke/death or AF admissions</td>
</tr>
<tr>
<td>Larsen et al. (2015)</td>
<td>Normal middle aged persons without known cardiovascular disease</td>
<td>48-h Holter on inclusion</td>
<td>Prospective (association between ESVEA and strokes or death)</td>
<td>678 subjects (41.4%; 6.3 years)</td>
<td>Median age 64.5 (SD 6.8)</td>
<td>ESVEA: More than 30 APCs per hour or any 20 APCs in run</td>
<td>After adjusting for baseline risk factors ESVEA was associated with ischemic stroke when censoring subjects at time of AF (HR 1.96; p &lt; 0.05). 85% of individuals with ESVEA who develop stroke had their stroke before atrial fibrillation. The annual stroke risk in patients with ESVEA and a CHA2DS2-VASc score ≥2 was 2.4% per year which is similar to comparable patients with AF</td>
</tr>
<tr>
<td>All new patients seen at the cardiovascular clinic</td>
<td>24-h Holter Retrospective registry (incident AF)</td>
<td>2.589 subjects (44.5%); Mean 571.4 (606.4) days</td>
<td>Median age 54.2 (15.5)</td>
<td>Frequent APCs were defined as more than 102 beats/day (the top quartile)</td>
<td>The incidence of new AF was 2.7 for patients with less than 102 APCs/day versus 37.7 per 1000 patient years for patients with frequent APCs. Adjusted Hazard Ratios for frequent APCs compared with nonfrequent APCs was 9.49 (p&lt;0.001).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients with cryptogenic stroke</td>
<td>24-h in hospital Holter monitoring Subsequent monitoring with implantable loop recorder (Reveal XT)</td>
<td>Incident AF during FU 70 patients (39%; 536 days)</td>
<td>58.8±13.4 N.A.</td>
<td>12/70 (7.6%) had AF during FU Median number of APCs was 1.5 per hour. Patients with AF had a median of 22.8 APCs/h versus 1.2 APCs/h in non-AF patients (p&lt;0.0001). Patients in the upper quartile of APCs (&gt;14.1/h) and short runs (&gt;0.2/h) had a relative risk of 4.0 (CI 1.1–14.6; P=0.04) and 6.9 (CI 1.8–26.7; P=0.005) for future AF, respectively</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Participants</td>
<td>Methodology</td>
<td>Characteristics</td>
<td>Findings</td>
<td>Summary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>--------------</td>
<td>-------------</td>
<td>----------------</td>
<td>----------</td>
<td>---------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gladstone et al. (2015)</td>
<td>Patients with cryptogenic stroke (EMBRACE Trial)</td>
<td>24-hour baseline Holter followed by a 30-day external-belt event recorder</td>
<td>Incident AF during follow up</td>
<td>237 patients without AF history and normal sinus rhythm on admission</td>
<td>N.A.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vinther et al. (2016)</td>
<td>Patients with ischaemic stroke</td>
<td>48-h in-hospital continuous cardiac telemetry</td>
<td>Prospective (combined primary endpoint was a recurrent ischemic stroke/TIA or death)</td>
<td>565 patients in SR (44.6%; 4 years)</td>
<td>Patients without runs of APCs: mean age 69.9 years (13.5) Patients with runs: 75.4 y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vinther et al. (2017)</td>
<td>Patients with ischaemic stroke</td>
<td>24-h Holter on inclusion and 48-h Holter at 6 – and 12 month FU</td>
<td>Prospective (association between ESVEA and recurrent stroke or death)</td>
<td>256 patients (45%; 32 months) 89 had AF and 167 were in SR at inclusion</td>
<td>Mean age 73 (12.6) More than 14 APCs per hour or 3 or more runs of premature atrial complexes per 24 hours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alhede et al. (2017)</td>
<td>Patients with paroxysmal AF participating in the MANTRA PAF trial</td>
<td>At baseline and 3, 6, 12, 18 and 24 months follow-up patients underwent</td>
<td>Prospective RCT (MANTRA PAF trial)</td>
<td>260 patients randomised to either AAD (N = 132) or CA (N = 128).</td>
<td>Patients were allocated according to low, moderate and high APC burden defined as 0–25</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The probability of AF increased from <9% among patients with <100 APCs/24 h to 9% to 24% in those with 100 to 499 APCs/24 h, 25% to 37% with 500 to 999 APCs/24 h, 37% to 40% with 1000 to 1499 APCs/24 h, and 40% beyond 1500 APCs/24 h.
| 7-day Holter monitoring to assess SVEC and AF burden | APCs/day, 25–100 APCs/day and >100 APCs/day in correspondence to a report from Varounis et al. | followed by a decrease whereas after AAD an early decrease was observed. Lower SVEC burden was highly associated with lower AF burden during follow-up especially after CA. |

**Abbreviations:**
APCs: Atrial Premature Contractions; ESVEA: excessive supraventricular ectopic activity; AF: Atrial Fibrillation; SR: Sinus rhythm; N.A.: data not available. AA: antiarrhythmic medication; CA: Catheter ablation.